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ABSTRACT	OF	DISSERTATION	
	
	
	
	
Characterizing Consumption, Dependence, 
 and the role of Glucocorticoids in an  
Animal Model of Voluntary Ethanol Consumption  
	
Alcohol	abuse	disorders	(AUD)	represent	a	serious	worldwide	health	problem	with	
far	 reaching	 social,	 financial,	 and	 interpersonal	 implications.	 One	 of	 the	 most	
devastating	facets	of	these	disorders	is	the	propensity	to	relapse	following	periods	
of	 abstinence.	 Ethanol	 withdrawal	 (EWD)	 is	 believed	 to	 promote	 relapse	 by	
increasing	anxiety	and	craving,	and	may	contribute	to	the	development	of	cognitive	
decline	associated	with	long‐term	dependence.	Clinical	data	suggest	that	stress	also	
plays	a	main	role	in	both	the	development	of	AUD	as	well	as	relapse	to	drinking.	As	a	
physiological	stressor,	EtOH	elevates	levels	of	stress	hormones	(cortisol	in	humans,	
corticosterone	 (CORT)	 in	 the	 rat).	Both	CORT	and	EtOH	have	been	shown	 to	alter	
the	 composition,	 function,	 and	 activity	 of	 the	 N‐methyl‐D‐aspartate	 (NMDA)	
receptor,	 and	 in	 particular,	 the	 NR2B	 subunit	 of	 this	 receptor.	 These	 alterations	
have	 been	 suggested	 to	 mediate	 EWD,	 which	 may	 negatively	 impact	 abstinence	
rates.	 This	 synergistic	 interaction	 between	 EtOH	 and	 CORT	 may	 present	 a	
therapeutic	target	for	the	treatment	of	EWD.	In	fact,	data	suggest	that	blocking	the	
glucocorticoid	 receptor,	 which	 is	 a	 main	 target	 for	 CORT,	 with	 RU‐486	 could	
promote	 abstinence,	 as	 treatment	 with	 the	 drug	 has	 been	 shown	 to	 reduce	
consumption	and	the	development	dependence,	as	well	as	the	severity	of	EWD	and	
the	 cognitive	 deficits	 following	 EWD.	 However,	 these	 latter	 effects	 have	 not	 been	
validated	 in	 models	 of	 voluntary	 EtOH	 consumption.	 As	 there	 is	 considerable	
evidence	that	active	versus	passive	intake	can	significantly	impact	neuroadaptations	
to	ethanol	this	 is	an	 important	consideration.	These	studies	sought	to	characterize	
consumption	 and	 evaluate	 the	development	of	 dependence	 in	 a	 chronic	 voluntary	
model	 of	 intermittent	 access	 (IA)	 to	 EtOH.	 CORT	 plasma	 levels	 and	 protein	
expression	of	the	glucocorticoid	and	NR2B	receptors	were	measured	during	and/or	
following	exposure.	Finally,	to	assess	the	role	of	CORT	in	EtOH	consumption	and	the	
development	of	dependence,	the	glucocorticoid	receptor	antagonist	ORG‐34517	was	
administered	during	access	to	EtOH.	IA	access	to	20%	EtOH	produced	varying	levels	
of	 consumption	 (2.0‐6.7g/kg/24hr	 exposure)	 and	 blood	 EtOH	 levels	 (6.3‐116.9	
mg/dl),	 but	 did	 not	 significantly	 affect	 food	 consumption	 or	weight	 gain.	 Baseline	
CORT	 levels	 were	 found	 to	 be	 predictive	 of	 subsequent	 EtOH	 consumption	 and	
levels	of	consumption	were	sufficient	to	elevate	CORT	levels	following	one	hour	of	
EtOH	 exposure.	 Further,	 IA	 to	 EtOH	 was	 sufficient	 to	 produce	 dependence,	 as	
measured	 by	 elevations	 in	 the	 acoustic	 startle	 reflex	 following	 26	 hours	 and	 five	
days	 of	 withdrawal.	 No	 alteration	 in	 protein	 expression	 was	 observed	 regarding	
either	 the	 NR2B	 or	 glucocorticoid	 receptors	 and	 exposure	 to	 ORG‐34517	 had	 no	
effect	on	consumption	or	withdrawal.		
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Chapter	1	
	
INTRODUCTION	
	
	
Issues	with	Alcohol	Use		
	 Alcohol	 use	 is	 prevalent	 in	 America,	 with	 60‐70%	 of	 the	 population	
reportedly	 consuming	 at	 least	 one	 alcoholic	 beverage	 during	 his	 or	 her	 lifetime	
(NIH,	2010).	 It	 is	present	when	we	celebrate	with	our	family	and	friends,	or	when	
we	struggle	through	our	most	difficult	times.	A	question	that	has	plagued	the	public	
and	 scientists	 alike	 is	why	 some	 individuals	 can	 use	 alcohol	 socially	while	 others	
develop	an	addiction	to	the	drug,	which	can	take	a	lifetime	to	break.		Indeed,	in	the	
United	States	an	estimated	30‐40%	of	people	who	drink	will	develop	an	alcohol	use	
or	abuse	disorder,	with	an	estimated	76	million	people	diagnosed	with	an	alcohol	
use	disorder	 (AUD)	worldwide	(WHO,	2004).	The	effects	on	society	are	many	and	
include	 poor	 health	 and	 increased	 mortality,	 increased	 violence	 and	 crime,	
marginalization	 of	 those	 affected,	 and	 loss	 of	 productivity.	 In	 fact,	 the	 cost	 of	
excessive	alcohol	use	in	the	United	States	yielded	a	median	of	$2.9	billion	dollars	in	
2006,	which	results	in	an	average	cost	of	$1.91	for	each	drink,	per	state	(Sacks	et	al,	
2013).	Treating	AUDs	 is	difficult,	 indicative	of	 the	high	rates	of	 relapse	associated	
with	the	disorder.	Reports	from	alcohol	dependent	individuals	indicate	that	stress	is	
a	main	 factor	 in	 relapse	 to	 drinking	 (Pohorecky,	 1991;	Weiss	&	Porrino,	 2002),	 a	
finding	that	can	be	replicated	in	preclinical	research	(recently	reviewed	by	Martin‐
Fardon	&	Weiss,	2013).		The	association	between	stress	and	alcohol	is	complex,	but	
provides	 researches	 with	 a	 possible	 therapeutic	 target	 in	 the	 treatment	 against	
alcohol	use	and	abuse	disorders.		
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Alcohol	and	the	Hypothalamic‐Pituitary‐Adrenal	Axis	
The	stress	response	is	a	biological	adaptation	that	is	elicited	when	there	is	a	
transition	 in	 the	 physiological	 or	 behavioral	 state.	 Such	 changes	 include	 the	
transition	 from	 sleep	 to	 wakefulness	 or	 from	 restfulness	 to	 escape.	 In	 the	 latter	
transition	the	stress	response	plays	a	crucial	role	in	the	overall	health	and	survival	
of	 the	 organism.	 The	 hypothalamic‐pituitary‐adrenal	 (HPA)‐axis	 is	 an	 integral	
component	of	 the	stress	response,	activation	of	which	culminates	 in	 the	release	of	
glucocorticoids	 (cortisol	 in	 human;	 corticosterone	 (CORT)	 in	 the	 rat	 or	 mouse).	
Glucocorticoids	can	release	and	redirect	stored	energy	in	times	of	crisis	but	can	also	
initiate	 long	 lasting	 adaptations	 in	 several	 different	 organs,	 including	 the	 brain.	
Activation	 of	 the	 HPA‐axis	 begins	 with	 the	 periventricular	 nucleus	 (PVN)	 of	 the	
hypothalamus,	 which	 receives	 input	 from	 many	 different	 regions	 of	 the	 central	
nervous	system	(CNS).	When	one	of	these	regions	detects	a	challenging	or	aversive	
stressor,	it	initiates	the	release	of	corticotrophin‐releasing	factor	(CRF)	and	arginine	
vasopressin	 (AVP)	 from	 the	 PVN	 into	 the	 portal	 blood	 circulation.	When	 released	
onto	the	anterior	pituitary	gland,	these	neurohormones	act	 in	concert	to	stimulate	
the	 release	 of	 adrenocorticotropin	 hormone	 (ACTH).	 ACTH	 then	 travels	 to	 the	
adrenal	gland	via	systemic	blood	circulation	to	initiate	the	synthesis	and	release	of	
glucocorticoids.	 The	 secretion	 of	 glucocorticoids	 provide	 a	 mechanism	 of	 both	
positive	 (amygdala)	 and	 negative	 (hippocampus	 and	 medial	 prefrontal	 cortex)	
feedback	 for	 the	 system	 (reviewed	 by	 Herman	 et	 al,	 2003;	 Herman,	 2012).	
Glucocorticoids	 can	 exert	 both	 genomic	 and	 nongenomic	 changes	 via	 the	
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adrenocorticosteroid	 receptors,	 the	 mineralocortocoid	 (MR)	 and	 glucocorticoid	
receptors	(GR).			
	 Alcohol	has	been	characterized	as	a	promiscuous	drug,	as	it	affects	an	array	
of	biological	processes	through	a	myriad	of	different	mechanisms.	One	such	process,	
which	 has	 received	 particular	 attention,	 is	 the	 influence	 alcohol	 exerts	 upon	 the	
HPA‐axis.	 Though	 a	 host	 of	 factors	 can	 influence	 this	 interaction,	 including	 dose,	
duration	of	exposure,	route	and	type	of	administration	(active	vs.	passive),	and	prior	
drug	exposure,	 there	are	 common	mechanisms	by	which	ethanol	 (EtOH)	activates	
the	 stress	 response.	As	 explained	 above,	 CRF	 synthesis	 and	 release	 from	 the	PVN	
represents	 the	 initial	 step	 in	HPA‐axis	 activation.	 EtOH	 administered	 directly	 into	
the	PVN	can	 increase	CRF	release	and	upregulate	CRF	receptor	(CRFR)	expression	
(Rivest	&	Rivier,	1994;	Lee	et	al.,	2005).	Using	a	hypothalamic	primary	cell	line,	Li	et	
al.	(2005)	found	that	exposure	to	EtOH	increased	CRF	gene	transcription	and	mRNA	
levels,	 resulting	 in	 elevated	 CRF	 secretion,	 effects	 which	 were	 blocked	 with	 the	
addition	of	either	a	cAMP	antagonist	or	PKA	inhibitor.		Together,	these	data	suggest	
that	EtOH	can	act	directly	to	stimulate	the	stress	response.	However,	EtOH	can	affect	
the	 HPA‐axis	 through	 less	 direct	 mechanisms	 as	 well,	 including	 activation	 of	 the	
catecholaminergic	 system	 (reviewed	 by	 Allen	 et	 al.,	 2011).	 As	 the	 main	
noradrenergic	 region	of	 the	brain,	 the	 locus	 coeruleus	 (LC)	plays	 a	 central	 role	 in	
this	interaction	(Reyes	et	al,	2006).	Lesioning	this	region	resulted	in	the	elimination	
of	ACTH	release	following	EtOH	injection,	while	lesions	to	the	minor	medullary	cell	
groups	 that	project	 onto	 the	PVN	 resulted	 in	 a	decrease	 in	CRF	 immunoreactivity	
(Allen	et	al,	2011).	Together,	these	studies	demonstrate	but	a	portion	of	the	ways	in	
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which	EtOH	exposure	can	produce	elevations	in	HPA‐axis	activity	and	are	suggestive	
of	how	complex	the	problem	of	treating	AUDs	can	become.		
	 	
Alcohol	Use	and	Stress	in	the	Human	Population	
Clinical	 research	 conducted	 over	 the	 past	 20	 years	 has	 demonstrated	 a	
complex	 association	 between	 stress	 and	 drug	 abuse,	 including	 the	 development	
AUDs.	 Anecdotally,	 it	 is	 almost	 a	 tradition	 to	 relax	 with	 a	 glass	 of	 wine	 or	 other	
alcoholic	drink	following	a	particularly	stressful	day	(e.g.	writing	one’s	dissertation).	
More	 insidiously,	 a	 recovering	 alcoholic	 may	 be	 driven	 to	 relapse	 following	 a	
difficult	 day	 or	 major	 life	 stressor.	 In	 fact,	 major	 stressors	 such	 as	 losing	 a	 job,	
moving,	 or	 experiencing	 a	 catastrophic	 event	 are	 associated	with	 lifetime	 alcohol	
consumption	 and	 risk	 of	 developing	 an	AUD	 (Veenstra	 et	 al,	 2006).	 However,	 the	
question	 as	 to	why	 these	 external	 risk	 factors	 induce	 some	 individuals	 to	 alcohol	
dependence,	while	others	remain	unaffected,	can	be	answered	in	part	by	genetics.		
Identifying	genes	that	may	contribute	to	the	development	of	alcoholism	has	
been	 difficult,	 as	 the	 disease	 is	 complex	 and	 likely	 results	 from	 the	 interaction	 of	
many	genes.	However,	while	 there	 are	numerous	 candidate	 genes	 that	 researches	
are	 investigating,	 there	 remains	only	 two	 that	have	been	definitively	 linked	 to	 the	
disease	 (reviewed	 by	 Zimmerman,	 2004).	 These	 genes	 code	 for	 enzymes	 that	
regulate	 alcohol	 metabolism,	 alcohol	 dehydrogenase	 (ADH)	 and	 aldehyde	
dehydrogenase	(ALDH),	and	are	unequally	distributed	among	individuals	with	and	
without	AUDs.	Genetic	polymorphisms	that	confer	high	levels	of	alcohol	metabolism	
are	 less	 likely	 to	occur	 in	alcohol	dependent	populations,	whereas	 the	converse	 is	
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true	 of	 polymorphisms	 resulting	 in	 low	 metabolic	 activity	 (reviewed	 in	
Zimmermann	 et	 al.,	 2004).	 It	 is	 understandable	 how	 a	 biological	 process	 such	 as	
alcohol	 clearance	can	 influence	an	 individual’s	propensity	 for	alcoholism,	but	how	
an	individual	reacts	to	stress	also	appears	to	be	a	contributing	factor,	and	which	is	in	
turn	mediated	by	one’s	genetic	profile.	Twins	studies	have	been	used	to	determine	
that	 the	 stress	 response	 is	 a	 heritable	 characteristic,	 with	 rates	 for	 HPA‐axis	
reactivity	as	high	as	97%	(Federenko	et	al.,	2004),	while	heredity	for	basal	cortisol	
levels	are	around	62%	(Bartels	et	al,	2003).	As	having	an	alcoholic	in	the	family	acts	
as	 a	 predictor	 for	 developing	 the	 disease,	 studies	 compared	 the	 stress	 response	
between	individuals	who	are	family	history	negative	(FHN)	to	those	who	are	family	
history	 positive	 (FHP)	 for	 alcoholism.	 Data	 reveal	 that	 FHP	 subjects	 displayed	 a	
significantly	altered	stress	response	under	clinical	conditions	with	regards	to	ACTH	
and	cortisol	secretion,	including	a	hypersensitive	response	to	psychosocial	stressors	
(reviewed	by	Uhart	&	Wand,	2008;	and	also	Zimmerman	et	al,	2007).	Interestingly,	
polymorphisms	in	the	GR	have	been	shown	to	confer	elevated	levels	of	basal	cortisol	
secretion	 (Rosmond	et	al,	2002),	greater	glucocorticoid	sensitivity	 (Lambert	et	al.,	
1998),	 increased	 salivary	 cortisol	 response	 following	psychosocial	 stress	 (Wust	 et	
al.,	 2004),	 and	 to	 be	 associated	with	 age	 of	 onset	 of	 alcohol	 abuse	 in	 adolescents	
(Desrivieres	eta	al.,	2010).	These	data	suggest	 that	cortisol	 levels	and	GC	receptor	
state	 can	 confer	 sensitivity	 for	 developing	 an	 AUD	 and	 that	 these	 factors	 are	
influenced	 by	 genetics.	 Further	 investigations	 into	 this	 system	 may	 result	 in	
identifying	 cellular	 and	molecular	 targets,	which	 could	 lead	 to	pharmacotherapies	
for	the	treatment	of	AUDs	and	the	relapse	to	drinking.			
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The	Study	of	Ethanol	Exposure	and	Stress	in	Animal	Studies	
Preclinical	 investigations	 into	 the	 interaction	 between	 stress	 and	 EtOH	
consumption	 have	 yielded	 equivocal	 results,	which	 appear	 to	 be	 dependent	 upon	
the	type	of	stress	(chronic	or	acute/sub‐chronic)	or	EtOH	(chronic	or	intermittent)	
exposure	used.	A	recent	meta‐analysis	on	this	issue	was	conducted	by	Becker	et	al.	
(2013)	and	concluded	that,	 in	general,	EtOH	consumption	was	either	decreased	or	
remained	unchanged	following	exposure	to	acute	or	sub‐chronic	stress	procedures	
(e.g.,	 foot	 shock,	 restraint,	 isolated	 housing),	 while	 chronic	 stress	 (e.g.,	 maternal	
separation,	 shift	 in	 circadian	 cycle,	 chronic	 variable	 stress)	 elevated	 consumption	
with	 the	most	 robust	 elevations	occurring	 in	 adulthood	 following	 stress	 exposure	
during	 adolescence.	 	 Interestingly,	 the	 group	 determined	 that	 the	 stress	 of	 EtOH	
exposure,	 in	 and	of	 itself,	 is	 sufficient	 to	 reliably	 elevate	EtOH	consumption	when	
the	drug	is	presented	in	a	chronic	yet	intermittent	fashion.	This	final	observation	is	
particularly	reflective	of	the	escalation	into	alcohol	dependence	seen	in	the	human	
population,	which	 is	characterized	by	bouts	of	 intoxication,	punctuated	by	periods	
of	abstinence,	following	which,	consumption	often	escalates.		
	
Models	of	Ethanol	Exposure	in	Rodents	
Preclinical	 studies	 of	 EtOH	 exposure	 are	 presented	 with	 a	 particular	
challenge,	as	rodents,	which	are	most	often	used,	do	not	readily	self‐administer	the	
drug	 in	 levels	 sufficient	 to	 produce	 intoxication	 and	dependence.	 It	 is	 common	 to	
use	 inbred	 or	 selectively	 bred	 rodents	 (e.g.,	 C57/BL6	mouse,	 P	 rat,	HAD	 rat)	 that	
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have	 been	 developed	 to	 express	 key	 traits	 of	 alcoholism,	 such	 as	 high	 EtOH	
preference	 and	 consumption,	 as	 intoxication	 and	 dependence	 can	 be	 readily	
induced.	Significant	contributions	 to	our	understanding	of	 the	mechanisms	behind	
alcohol	 abuse	 have	 been	 gained	 by	 using	 such	 genetically	 homogeneous	 strains.	
However,	these	animal	models	can’t	fully	represent	the	disease	of	alcoholism,	as	it	is	
influenced	 by	 multiple	 genetic	 and	 environmental	 factors,	 as	 well	 as	 by	 gene	 x	
environment	 and	 gene	 x	 gene	 interactions	 (Becker,	 2012;	 Crabe,	 2002;	 Enoch	 &	
Goldman,	2001;	Johnson	et	al.,	1998).		
Researchers	 have	 developed	 several	 investigative	 techniques	 to	 obtain	
intoxication	in	the	outbred	rodent.	These	 include	passive	models	of	exposure	such	
as	 intragastric	 intubation,	 intraperitoneal	 injection,	 and	 exposure	 via	 EtOH	 vapor	
chambers.	However,	passive	versus	active	drug	administration	can	alter	release	and	
turnover	 of	 neurotransmitters,	 including	 those	 important	 to	 the	 development	 of	
alcohol	use	disorders	(as	reviewed	by	Jacobs	et	al.,	2003).	For	example,	release	and	
turnover	 of	 dopamine	 and	 glutamate	 are	 differentially	 affected	 in	 the	 nucleus	
accumbens	 depending	 on	 a	 passive	 (yolked	 control)	 versus	 active	 (operant	 self‐
administration)	 delivery	 of	 cocaine	 (Dworkin,	 1993;	Hemby	 et	 al,	 1997).	 Delivery	
dependent	 changes	 have	 been	 found	 with	 other	 drugs	 of	 abuse	 including	
amphetamine	 (Di	 Ciano,	 et	 al.	 1998)	 and	 morphine	 (Smith	 et	 al,	 2003).	 Most	
recently,	 voluntary	 but	 not	 passive	 (gavage)	 administration	 of	 EtOH	 produced	
alterations	 in	 anxiety	 following	 14	 days	 of	 exposure	 (Mitchell	 et	 al.,	 2012).		
Together,	 these	findings	suggest	that	the	effects	of	drugs	of	abuse,	 including	EtOH,	
may	 not	 be	 derived	 simply	 by	 their	 pharmacological	 actions	 but	 instead	manifest	
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due	to	an	interaction	between	drug	and	cognitive	processes	(Jacobs	et	al.,	2003).	As	
the	development	of	pharmacological	targets	is	driven	by	neuroadaptations	resulting	
from	drug	administration,	it	is	crucial	that	preclinical	models	properly	reflect	these	
neuroadaptive	states.		
	
Alcohol,	Stress,	and	the	NMDA	Receptor	 	
Excitatory	 tone	 in	 the	 CNS	 is	 primarily	 regulated	 via	 the	 gamma‐amino	
butyric	acid	(GABA)	and	glutamate	neurotransmitter	systems,	with	GABA	providing	
inhibitory	control	and	glutamate	providing	excitatory	control.	Acutely,	EtOH	targets	
these	 systems,	 producing	 an	 overall	 inhibitory	 effect	 (Popp	 et	 al.,	 1999).	 As	 a	
consequence	of	prolonged	EtOH	exposure	and	the	accompanying	neural	inhibition,	
compensatory	neuroadaptions	alter	 the	CNS	to	regain	and	maintain	a	homeostatic	
level	 of	 activity	 (reviewed	by	Kumari	 and	Ticku,	 2000).	 It	 is	 suspected	 that	 these	
neuroadaptations	 are	 associated	with	 the	 development	 of	 dependence,	 as	well	 as	
symptoms	 of	 ethanol	 withdrawal	 (EWD),	 including	 elevated	 anxiety	 and	 seizure	
activity	(reviewed	by	Becker,	2010).	These	neuroadaptations	include	changes	in	the	
composition,	 function,	 and	 activity	 of	 the	 NMDA	 receptor	 (elegantly	 reviewed	 in	
Prendergast	 &	 Mulholland,	 2012).	 Of	 particular	 interest	 have	 been	 the	 EtOH‐
mediated	 alterations	 in	 the	 stoichiometry	 of	 the	 NMDA	 receptor,	 as	 subunit	
composition	has	direct	implications	regarding	channel	kinetics	(Erreger	et	al.,	2005;	
Vicini	et	al.,	1998),	synaptic	localization	(Kohr,	2006),	and	protein	binding	partners	
(Hardinham	 et	 al.,	 2002;	 Vanhoutte	 &	 Bading,	 2003;	 Ivonov	 et	 al.,	 2006).	 Using	
recombinant	 NMDA	 receptors,	 Erreger	 and	 others	 (2005)	 have	 shown	 that	
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NR1/NR2A	 heteromers	 had	 faster	 gating	 time	 than	 did	 NR1/NR2B.	 However,	
NR1/NR2B	 heteomers	 had	 longer	 channel	 activation	 duration	 and	 therefore	
conferred	greater	total	conductance	of	calcium.	Additionally,	the	NR2B	subunit	can	
alter	channel‐ligand	binding	and	confer	increased	excitotoxicity	(Butler	et	al.,	2010).	
Chronic	EtOH	exposure	has	been	associated	with	increased	mRNA	(Anji	&	Kumari,	
2006)	and	protein	expression	(Carpenter‐Hyland	et	al,	2006;	Pian	et	al.,	2010)	of	the	
NR2B	subunit;	however	others	have	found	no	such	changes	(Chandler	et	al.,	2007;	
Rudolph	et	al.,	1997).	Interestingly,	exposure	to	CORT	has	also	been	associated	with	
elevations	of	NR2B	protein	 (Weiland	 et	 al,	 1997).	 Several	 groups	have	 found	 that	
trafficking	 of	 the	 NR1/NR2	 to	 the	 synaptic	 membrane	 is	 mediated	 by	 EtOH	
(Carpenter‐Hyland	et	al.,	2004;	Hendrickson	et	al.,	2003;	Qiang	et	al.,	2007).	Others	
have	 found	 increased	 neurotransmission	 following	 EtOH‐dependent	
phosphorylation	 of	 the	NR2B	by	 the	 tyrosine	 kinsase	 Fyn	 (Miyakawa	 et	 al.,	 1997;	
Yaka	 et	 al.,	 2003;	 Yaka	 et	 al.,	 2003).	 Additionally,	 the	 NR2B	 subunit	 includes	 a	
positive	 allosteric	modulatory	 site	 for	polyamines	 (Mony	et	 al,	 2009;	 reviewed	by	
Prendergast	&	Mulholland,	2012).	Exposure	to	CORT	(Cousins	et	al.,	1984)	and	EtOH	
(Williams	1994),	including	EWD	(Williams,	1994),	elevates	synthesis	of	polyamines	
by	upregulating	the	ornithine	decarboxylase	(ODC)	enzyme	within	the	brain	(Cousin	
et	 al.,	 1982).	 Recently,	 it	 was	 reported	 that	 long‐term	 co‐exposure	 to	 EtOH	 and	
CORT	sensitized	hippocampal	tissue	to	insult	following	the	withdrawal	of	EtOH,	the	
effects	 of	 which	 were	 mediated	 by	 the	 NR2B	 receptor	 (Butler	 et	 al,	 in	 press).	
Together,	 these	 data	 provide	 overwhelming	 evidence	 that	 stress	 and	 EtOH	 have	
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several	different	routes	by	which	they	can	independently	and	jointly	alter	NMDAr‐	
dependent	neurotransmission.	
	
Alcohol	and	the	Glucocorticoid	Receptor	
The	MR	and	GR	are	the	primary	targets	for	corticosteroid	hormones	in	both	
humans	and	rodents.	 	The	receptor	names	are	derived	from	the	primary	processes	
they	influence	in	the	periphery,	namely	mineral	balance	and	gluconeogenesis.	Both	
receptor	 types	 have	 been	 found	 in	 brain	 tissue.	MR	 distribution	 is	 restricted,	 but	
includes	 high	 expression	within	 the	 hippocampal	 formation.	 GRs	 are	 ubiquitously	
expressed	 on	 both	 neurons	 and	 glia	 but	 are	 more	 concentrated	 in	 certain	 brain	
regions,	 including	 the	hippocampus	and	PVN.	CORT	has	a	much	higher	affinity	 for	
the	 MR,	 with	 full	 occupation	 occurring	 at	 low	 physiological	 levels	
(~10ng/ml=29nM);	 whereas	 the	 GR	 is	 only	 partially	 occupied	 at	 such	 levels	 and	
becomes	 fully	 occupied	 during	 times	 of	 stress,	 when	 a	 CORT	 surge	 occurs	
(~400ng/ml=1.12µM)	 (deKloet	 et	 al,	 1993).	 	 For	 this	 reason,	 GRs	 have	 been	 of	
specific	 interest	with	 regards	 to	 EtOH	 related	 changes	 in	 the	 CNS.	 GRs	 are	 found	
within	 the	 cytoplasm	 of	 cells,	 where	 they	 are	 inactively	 bound	 to	 protein	
chaperones.	 Once	 occupied	 by	 CORT,	 the	 chaperone	 dissociates,	 and	 the	 receptor	
complex	 translocates	 to	 the	 nucleus,	 where	 either	 transactivation	 or	
transrepression	may	occur.	Transactivation	is	initiated	when	the	receptor	complex	
merges	 with	 DNA	 to	 form	 a	 homodimer	 at	 the	 glucocorticoid	 response	 element	
(GRE),	most	often	resulting	in	gene	transcription	(reviewed	in	Jenkins	et	al.,	2001).	
Alternately,	 the	 receptor	 complex	 can	 interact	 with	 other	 transcription	 factors,	
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thereby	 suppressing	 or	 facilitating	 their	 effects,	 a	 phenomena	 referred	 to	 as	
crosstalk	 (reviewed	 in	 Kassel	 &	 Herrlich,	 2007).	 Through	 transactivation	 and	
crosstalk,	 and	 coupled	 with	 the	 fact	 that	 there	 are	 many	 known	 isoforms	 of	 the	
receptor,	 GRs	 are	 able	 to	 produce	 wide	 influence	 on	 protein	 expression,	 cellular	
activity,	and	behavioral	outcomes.	While	this	is	infinitely	adaptive	to	the	organism,	
this	 level	 of	 complexity	 presents	 a	 challenge	 for	 researchers	 when	 attempting	 to	
investigate	the	already	complex	stress	response.	
GR	activation	has	important	consequences	on	EtOH	consumption,	which	has	
well	been	characterized	in	animal	models.	For	example,	elevated	levels	of	CORT	can	
enhance	EtOH	consumption	(Fahlke	et	al.,	1994a,	b;	Falke	&	Hansen,	1995;	Hansen	
et	 al.,	 1995),	 whereas	 adrenalectomy	 (ADX)	 (de	Witte	 et	 al,	 1996;	 Hansen	 et	 al.,	
1995,	Fahlke	et	al,	1994)	or	antagonizing	the	GR	are	effective	in	reducing	voluntary	
consumption	 (Koeig	 &	 Olive,	 2004).	 Additionally,	 antagonism	 of	 the	 GR	 has	 been	
shown	 to	 reduce	 behavioral	 signs	 of	 (Sharrett‐Field	 et	 al.,	 2013),	 and	 cognitive	
deficits	 (Jaquot	 et	 al.,	 2008)	 resulting	 from	 EWD.	 Further,	 ADX	 prior	 to	 EtOH	
exposure	has	been	shown	to	decrease	subsequent	EtOH	intake	(Fahlke	&	Eriksson)	
and	EtOH	preference	(Lambin	&	de	Witte,	1996)	in	selectively	bred	rat	lines,	while	
administration	of	CORT	restored	consumption	in	both	experiments.	It	 is	clear	that,	
at	 least	 in	 animal	 models	 of	 EtOH	 exposure,	 GR	 activation	 is	 able	 to	 mediate	
consumption.	
While	 GRs	 can	 affect	 EtOH	 intake,	 EtOH	 intake	 can	 also	 modulate	 GR	
expression.	 For	 example,	 a	 decline	 in	GR	mRNA	 in	 the	hippocampus	 (Eskay	 et	 al.,	
1995),	cortex	(Roy	et	al.,	2002;	Vendruscolo	et	al.,	2012),	amygdala	(Vendruscolo	et	
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al.,	2012),	and	PVN	(Roy	et	al.,	2002)	has	been	shown	following	EtOH	exposure	 in	
rodents.	 Such	 declines	 have	 been	 shown	 to	 persist	 up	 to	 24	 hours	 following	 the	
withdrawal	 of	 EtOH,	while	 elevations	 in	 GR	mRNA	were	 found	 during	 protracted	
abstinence	(Vendruscolo	et	al.,	2012).	However,	data	are	mixed	regarding	receptor	
alterations	both	during	and	 following	EWD	(see	Rachamin	et	 al.,	 1989;	 Spencer	&	
McEwen,	 1990).	 As	 previously	 discussed,	 the	 interaction	 between	 EtOH	 and	 GRs	
have	behavior	 consequences,	 as	manipulating	 levels	of	CORT	or	GR	activation	 can	
alter	consumption,	the	escalation	of	dependence,	and	the	severity	of	EWD.		
	 	
Acoustic	Startle	Reflex	
The	startle	reflex	can	be	elicited	by	a	sufficiently	sudden	and	intense	stimulus	
and	likely	manifests	to	defend	an	organism	from	predation	or	a	blow,	and	to	prepare	
for	 fight	 or	 flight.	 The	 reflex	begins	with	 eye‐lid	 closure,	which	 is	 followed	by	 the	
contraction	of	 facial,	 neck,	 and	 skeletal	muscles	 (Davis,	 1979).	This	 contraction	of	
musculature	 throughout	 the	 body	 is	 accompanied	 by	 the	 cessation	 or	 freezing	 of	
ongoing	behaviors	and	the	acceleration	of	heart	rate	(Davis,	1979).	The	startle	reflex	
can	be	experimentally	initiated	by	the	presentation	of	an	acoustic,	tactile,	or	visual	
stimulus	 in	 most	 mammals,	 including	 humans	 and	 rodents	 (reviewed	 by	 Koch,	
1998).	Importantly,	the	acoustic	startle	reflex	(ASR)	found	in	rodents	can	generalize	
to	humans,	a	fact	that	suggests	similar	neural	mechanisms	mediate	the	response	in	
both	 species	 (Geyer	 &	 Braff,	 1987;	 Braff	 et	 al.,	 2001).	 An	 additional	 benefit	 of	
employing	ASR	 is	 that	acoustic,	 tactile	or	visual	 stimuli	 can	be	combined	 to	either	
attenuate	 or	 enhance	 responding.	 For	 example,	 prior	 to	 the	 presentation	 of	 a	
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startling	tone,	the	delivery	of	an	acute	aversive	stimulus,	such	as	a	foot	shock,	will	
elevate	 the	 ASR,	 while	 the	 presentation	 of	 a	 non‐startling	 tone	 (prepulse)	 will	
attenuate	 the	 response	 (Davis	 1979;	 Geyer	 &	 Dulawa,	 2003;	 Koch	 1998).	
Additionally,	ASR	can	be	manipulated	through	conditioning	with	either	aversive	or	
appetitive	conditioned	stimulus/unconditioned	stimulus	pairing	(fear‐potentiated).	
ASR	 can	 be	 altered	 in	 magnitude	 by	 several	 stimuli,	 including	 stimulus	 intensity	
(Pilz	 et	 al.,	 1987),	 interstimulus	 interval	 (Davis,	 1979),	 genetics	 (Pilz	 et	 al.,	 2002),	
diurnal	 rhythm	 (Chabot	 &	 Taylor,	 1992),	 sensory	 environment	 (ie,	 background	
noise)	 (Geyer	 &	 Dulawa,	 2003)	 illumination	 (Walker	 &	 Davis	 1997),	 and	 drug	
manipulation	 (last	 reviewed	 by	 Davis,	 1979).	 In	 general,	 anxiogenic	 drugs	 (e.g.	
yohimbine)	elevate	ASR	in	humans	(Morgan	III	et	al.,	1993)	and	rats	(Powell	et	al.,	
2005),	 while	 anxiolytics,	 including	 benzodiazpaines,	 attenuate	 responding	 in	
humans	 (Rodríguez‐Fornells	 et	 al.,	 1999)	 and	 also	 rodents	 (Commissaris	 et	 al.,	
2003).				
Indicative	 of	 most	 reflex	 responses,	 the	 fundamental	 neural	 circuitry	
believed	to	conduct	ASR	is	rather	simple.	Briefly,	the	auditory	signal	is	conducted	by	
a	small	group	of	cells	within	 the	auditory	nerve,	 the	cochlear	root	neurons,	which	
terminate	directly	onto	the	nucleus	reticularis	pontis	caudalis.	Projections	from	this	
structure	 terminate	 onto	 the	 motor	 neurons	 of	 the	 face	 (eye	 blink	 and	 facial	
contraction)	 and	 spinal	 cord	 (whole	 body	 musculature	 contraction)	 (Davis	 et	 al.,	
1982;	 Lee,	 et	 al.,	 1996).	 Glutamate	 is	 the	 main	 excitatory	 neurotransmitter	
mediating	 this	 circuit,	 including	 activity	 at	 the	 glutamatergic	 AMPA	 and	 NMDA	
receptors	 (Ebert	 &	 Koch,	 1992;	 Krase	 et	 al.,	 1993),	 which	 is	 opposed	 by	 GABA	
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inhibition	 (Birnbaum	 et	 al.,	 1997).	 With	 one	 distinction	 regarding	 a	 bi‐phasic	
response	 to	 the	 eye	 blink	 reflex	 that	 is	 seen	 in	 humans,	 a	 similar	 pattern	 of	
responding	and	latency	have	been	observed	across	human	and	rat	species	(Meincke	
et	al.,	2002).	While	the	basic	ASR	is	mediated	by	three	synapses,	 the	neural	 inputs	
that	 are	 able	 to	 modulate	 the	 response	 are	 complex,	 involving	 several	 brain	
structures.	The	neural	pathway	believed	to	mediate	the	sensory‐gating	measure	of	
prepulse	 inhibition	 (PPI)	 involves	 a	 cortico‐striatio‐pallido‐pontine	 (CSPP)	 circuit	
that	can	be	regulated	by	the	limbic	system	(reviewed	in	Braff	et	al,	2001	(human);	
Swerdlow	et	al.,	2001	(animal)).	Regions	of	the	limbic	system	that	are	important	in	
mediating	 PPI	 include	 the	 hippocampus,	 prefrontal	 cortex	 (PFC)	 and	 medial	
prefrontal	cortex	(mPFC),	and	the	BLA	(Swerdlow,	2001).	
	
Acoustic	Startle	Reflex	in	Humans	
Alterations	 of	 ASR	 and	 PPI	 have	 been	 used	 to	 study	 numerous	 conditions	
occurring	 in	 the	 human	 population.	 Alterations	 in	 PPI	 have	 been	 associated	with	
schizophrenia	(Braff	et	al.,	2001;	Weike	et	al.,	2000),	obsessive‐compulsive	disorder	
(Swerdlow	 et	 al.,	 1993),	 Tourette	 syndrome	 (Swerdlow	 et	 al.,	 2001),	 attention	
deficit	 disorder	 (Ornitz	 et	 al.,	 1992),	 and	 post‐traumatic	 stress	 disorder	
(PTSD)(Grillon	et	al.,	1996;	reviewed	by	Braff	et	al.,	2001).	Further,	increases	in	the	
acoustic	 startle	 reflex	 have	 been	 found	 in	 individuals	 who	 suffer	 from	 anxiety	
(Grillon	et	al.,	1997),	depression	(Grillon	et	al.,	1997;Mneime	et	al.,	2008),	childhood	
abuse,	 or	 experience	 substance	 abuse	 (Grillon	 et	 al.,	 2008).	 In	 healthy	 subjects,	
alcohol	 suppresses	 the	 expression	 of	 ASR	 while	 PPI	 is	 either	 unaffected	 or	
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moderated	by	baseline	responding	(Grillon	et	al.,	1994;	Hutchison	et	al.,	1997).	In	a	
small	study	of	alcohol	dependent	individuals	experiencing	EWD	(n=8),	a	decrease	in	
PPI	 was	 found,	 with	 individuals	 previously	 experiencing	 delirium	 tremens	 (n=3)	
showing	 the	 greatest	 deficits	 (Keedwell	 et	 al.,	 2001).	 In	 a	 group	 of	 recently	
detoxified	heavy	drinkers	(meeting	DSM‐III‐R	requirements),	ASR	was	found	to	be	
elevated	as	 compared	 to	 control	 subjects	 (Krystal	 et	 al.,	1997).	Further,	 a	positive	
relationship	 was	 shown	 between	 the	 amplitude	 of	 the	 response	 and	 number	 of	
detoxification	episodes	 (Krystal	et	al.,	1997).	A	recent	study	suggests	 these	effects	
are	biphasic,	as	decreased	ASR	and	PPI	were	found	after	one	month	of	abstinence	in	
a	 similar	 population	 (Marin	 et	 al.,	 2012).	 Evidence	 suggests	 that	ASR	 and	PPI	 are	
potential	vulnerability	biomarkers	for	AUD	as	children	with	a	family	history	positive	
(FHP)	 for	 alcoholism	 show	 elevated	 baseline	ASR	 (Zimmermann	 et	 al.,	 2004)	 and	
impaired	PPI	(Grillon	et	al.,	1997).	Additionally,	in	young	adult	males	who	are	FHP,	
baseline	PPI	was	reduced	and	exposure	to	alcohol	did	not	dampen	ASR	to	the	same	
levels	as	those	seen	in	control	subjects	(Grillon	et	al.,	2000).			
	
Acoustic	Startle	Reflex	in	Animal	Models	
Preclinical	 investigations	 using	ASR	 and	 PPI	 to	 study	 the	 effects	 of	 alcohol	
have	 found	 no	 alterations	 in	 adulthood	 in	 either	 measure	 as	 a	 result	 of	 prenatal	
(Poter	&	Bernston	1987)	or	early	postnatal	(Woolfey	et	al.,	2003)	administration	of	
EtOH.	 However,	 when	 exposure	 occurred	 during	 adolescence,	 adult	 animals	 did	
show	evidence	of	decreased	inhibition	in	the	presence	of	the	prepulse	(Slawecki	&	
Ehlers,	2005).	Data	regarding	EtOH‐induced	changes	in	PPI	in	outbred	animals	are	
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mixed,	with	Jones	et	al	(1999),	finding	a	disruption	in	PPI,	while	other	groups	found	
no	significant	differences	(Sandback	et	al.,	1999;	Chester	&	Barrenha,	2007).	During	
EWD,	elevated	ASR	has	been	found	in	the	outbred	rodent	following	chronic	forced	
exposure	to	EtOH	(Pohorecky	&	Roberts,	1992;	Rassnick	et	al.,	1992;	Vandergriff	et	
al.,	 2000).	 Data	 collected	 in	 animals	 selectively	 bred	 for	 EtOH	 preference	 show	
reductions	in	EWD	in	animals	with	high	preference	for	EtOH,	as	compared	to	 low‐
preferring	animals	 (Jones	 et	 al.,	 2000;	Chester	 et	 al.,	 2003,	 2004,	 2005;	Chester	&	
Barrenha	2007).	In	fact,	 it	has	been	demonstrated	that	EWD‐associated	changes	in	
startle	 response	 and	 habituation	 to	 startle	 is	mediated	 in	 part	 by	 factors	 such	 as	
EtOH	preference	 and	 sensitivity	 to	EWD,	which	 is	 linked	 to	 preference	 (Gilliam	&	
Collins	 1986;	 Jones	 et	 al,	 2000;	 Dess	 et	 all,	 2005;	 Ponomarev	 &	 Crabbe,	 1999).		
Further,	 under	 EtOH	 naïve	 conditions,	 high	 preferring	 animals	 (P‐rat	 and	Wistar	
High	Preferring)	display	an	elevated	ASR	prior	 to	EtOH	exposure,	 as	 compared	 to	
non‐preferring	animals	of	the	same	strain	(Jones	et	al,	2000;	Acewicz	et	al.,	2012).		
However	 these	 results,	 both	 regarding	 ASR	 activity	 during	 EWD	 and	 EtOH‐naïve	
conditions,	 are	 in	 direct	 contrast	 with	 the	 human	 literature,	 discussed	 above.	
Differences	regarding	baseline	ASR	may	be	evident	due	to	previous	EtOH	exposure,	
as	 it	 is	 difficult	 to	 control	 for	 lifetime	 alcohol	 experience	 in	 humans.	 As	 for	 the	
disparity	 in	 EWD‐associated	 changes	 in	 ASR,	 it	 should	 be	 noted	 that	 the	 studies	
cited	 above	 used	 forced	 methods	 of	 EtOH	 exposure.	 Therefore,	 low‐consuming	
animals,	which	 tend	 to	have	high	sensitivity	 to	 the	effects	of	EWD,	were	 forced	 to	
consume	EtOH	and	served	as	the	comparison	groups	for	these	studies.	Additionally,	
experience	with	alcohol	can	also	influence	EWD‐associated	elevations	in	ASR	in	the	
17	
	
human	 population.	 Despite	 this	 conflicting	 data,	 it	 is	 evident	 that	 ASR	 could	 be	 a	
valuable	biomarker	for	the	development	of	alcohol	dependence.	
	
Experimental	Rationale	
Alcohol	abuse	disorders	represent	a	serious	worldwide	health	problem	with	
far‐reaching	 social,	 financial,	 and	 interpersonal	 implications.	 One	 of	 the	 most	
devastating	facets	of	these	disorders	is	the	propensity	to	relapse	following	periods	
of	 abstinence.	 EWD	has	 been	 linked	 to	 neuroadaptations	 that	 promote	 relapse	 by	
increasing	anxiety	and	craving.	Further,	EWD	may	contribute	to	the	development	of	
cognitive	 decline	 associated	 with	 long‐term	 dependence.	 EtOH	 exposure	 changes	
the	 composition,	 function,	 and	 activity	 of	 the	 N‐methyl‐D‐aspartate	 receptor	
(NMDAr),	 and	 in	 particular,	 the	 NR2B	 subunit	 of	 this	 receptor.	 Stress	 similarly	
affects	activity	of	this	receptor	system.	CORT,	the	primary	stress	hormone	found	in	
non‐human	mammals,	has	also	been	shown	to	alter	the	expression	and/or	function	
of	the	NMDAr.	As	EtOH	is	a	physiological	stressor,	it	is	reported	to	increase	levels	of	
plasma	CORT.	This	synergistic	interaction	between	EtOH	and	CORT	as	it	affects	the	
NMDAr	and	GR	could	present	a	therapeutic	target	in	the	treatment	of	EWD.	In	fact,	
data	 suggest	 that	 the	 GR	 antagonist	 mifepristone	 could	 promote	 abstinence,	 as	
treatment	with	 the	drug	has	been	 shown	 to	 reduce	 consumption	 (Koenig	&	Olive,	
2004	),	the	development	and	maintenance	of	EtOH	dependence	(Vendruscolo	et	al,	
2012),	as	well	as	and	decreasing	the	severity	of	EWD	(Sharrett‐Field	et	al,	2013)	and	
cognitive	deficits	 following	EWD	 (Jaquot	 et	 al,	 2008).	However,	 these	 effects	 have	
not	been	validated	in	preclinical	models	of	voluntary	EtOH	consumption.	As	there	is	
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considerable	 evidence	 that	 active	 versus	 passive	 drug	 intake	 can	 significantly	
impact	neuroadaptations	 to	EtOH,	 this	 is	an	 important	consideration	(Jacobs	et	al,	
2003;	Dworking	et	al,	1995).		
Study	 one	 of	 the	 following	 studies	 characterized	 consumption	 patterns	
resulting	from	a	voluntary	model	of	EtOH	exposure	and	also	the	ability	of	this	model	
to	produce	dependence,	as	defined	by	the	manifestation	of	EtOH	withdrawal	and	as	
measured	 by	 the	 acoustic	 startle	 reflex	 (ASR).	 It	was	 hypothesized	 that	 voluntary	
intermittent	access	to	20%	EtOH	solution	for	7	weeks	would	produce	elevations	in	
ASR	 and	 reductions	 in	 the	 habituation	 and	 inhibition	 of	 ASR	 during	 EWD.	 To	
determine	 the	 influence	 of	 CORT	 on	 consumption	 and	 dependence,	 plasma	 CORT	
levels	 were	 also	 assessed.	 Higher	 levels	 of	 baseline	 CORT	 were	 predicted	 to	 be	
associated	 with	 elevated	 consumption	 and	 resulting	 blood	 EtOH	 content.	 CORT	
levels	 assessed	 during	 acute	 and	 protracted	 EWD	 were	 expected	 to	 be	 elevated;	
levels	were	also	predicted	to	associate	with	levels	of	EtOH	consumption.	Following	
EtOH	exposure,	protein	levels	of	the	NMDA	NR2B	subunit	and	GR	were	assessed	in	
the	pre‐frontal	cortex	(PFC)	and	hippocampus.	Elevated	levels	of	both	GR	and	NR2B	
in	EtOH	exposed	animals	were	hypothesized	at	this	time	point.		
Study	 two	 was	 conducted	 to	 determine	 the	 effects	 administration	 of	 the	
selective	GR	antagonist,	11,21‐Bisphenyl‐19‐norpregnane	(ORG‐34517)	would	have	
on	voluntary	consumption	levels	and	subsequent	EWD.	EtOH	exposure	methods	as	
well	as	CORT	and	ASR	assessment	followed	those	described	above.	However,	during	
weeks	 7	 and	 8,	 a	 subset	 of	 animals	 received	 ORG‐34517	 or	 placebo	 control	
(Nutella®)	 prior	 to	 EtOH	 access.	 It	 was	 hypothesized	 that	 ORG‐34517	 would	
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decrease	 voluntary	 consumption	 of	 20%	 EtOH.	 Attenuation	 of	 EtOH‐dependent	
changes	 in	 ASR	 during	 EWD	were	 also	 anticipated.	 However,	 elevations	 in	 CORT	
were	 hypothesized	 in	 the	 ORG‐34517	 treated	 animals,	 as	 blocking	 the	 GR	 also	
blocks	 the	 natural	 negative	 feedback	 mechanism	 for	 the	 stress	 response.	
Assessment	of	protein	levels	were	similar	to	those	conducted	in	Study	1,	however,	
the	medial	 region	of	 the	pre‐frontal	 cortex	 (mPFC)	was	 isolated	 in	addition	 to	 the	
hippocampal	 region.	 GR	 and	 NR2B	 protein	 expression	 was	 assessed,	 as	 well	 the	
phosphorylation	 state	 of	 the	 NR2B	 receptor,	 which	 plays	 an	 important	 role	 in	
channel	 kinetics	 of	 NR2B‐containing	 receptors.	 EtOH‐associated	 elevations	 in	 GR,	
NR2B,	and	pNR2B	were	expected.		
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Chapter	Two	
INTERMITTENT	ACCESS	TO	20%	ETHANOL	PRODUCES	MEASURABLE	
WITHDRAWAL	AND	ALTERATIONS	IN	PLASMA	CORTICOSTERONE	LEVELS		
(Study	1;	Sharrett‐Field,	et	al.)	
	
Introduction	
	 An	 estimated	 60‐70%	 of	 the	 American	 population	 will	 consume	 alcohol	
during	his	or	her	lifetime,	and	30‐40%	of	these	individuals	will	develop	an	alcohol	
use	or	dependence	disorder	(NIH,	2010;	WHO,	2004	).	Clinical	studies	suggest	that	
people	often	drink	following	a	stressful	day	or	event	in	an	effort	to	“relax”.	In	stark	
contradiction,	 alcohol	 is	 a	 pharmacological	 stressor,	 activating	 the	 hypothalamic‐
pituitary	adrenal	axis	and	resulting	in	the	synthesis	and	release	of	stress	hormones	
(cortisol	 in	 the	 human;	 corticosterone	 (CORT)	 in	 the	 rodent).	 Understanding	 the	
interaction	 between	 stress	 and	 alcohol	 is	 imperative,	 as	 not	 only	 does	 stress	
encourage	social	drinkers	 to	 imbibe,	but	 the	occurrence	of	a	 stressful	event	 is	 the	
most	 commonly	 reported	 trigger	 for	 relapse	 to	 drinking	 in	 abstinent	 alcoholics	
(Pohorecky,	1991;	Weiss	&	Porrino,	2002).	In	fact,	prior	exposure	to	a	stressor	can	
enhance	 self‐administration	 of	 several	 drugs	 of	 abuse,	 including	 EtOH,	 in	 both	
humans	(reviewed	by	Enoch,	2011)	and	animals	(reviewed	by	Becker,	2010).			
	 It	is	well	accepted	that	both	alcohol	and	CORT	are	reinforcing	agents,	as	both	
activate	 the	 mesolimbic	 dopamine	 system	 (Piazza	 et	 al,	 1998;	 Gessa	 et	 al,	 1985;	
Mereu	 et	 al,	 1984).	 Elevated	 levels	 of	 CORT	 can	 enhance	 EtOH	 consumption	 in	
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animals	(Fahlke	et	al.,	1994a,	b;	Falke	&	Hansen,	1995;	Hansen	et	al.,	1995),	whereas	
adrenalectomy	 (de	Witte	 et	 al,	 1996;	 Hansen	 et	 al.,	 1995,	 Fahlke	 et	 al,	 1994)	 or	
antagonizing	 the	 glucocorticoid	 receptor	 (GR)	 (a	 primary	 receptor	 for	 CORT)	 are	
effective	 in	 reducing	 voluntary	 consumption	 (Koeig	 &	 Olive,	 2004).	 Additionally,	
antagonism	of	the	GR	has	been	shown	to	reduce	behavioral	signs	of	(Sharrett‐Field	
et	 al.,	 2013)	 and	 cognitive	 deficits	 resulting	 from	 EWD	 (Jaquot	 et	 al.,	 2008).	
Developing	treatments	for	use	during	EWD	is	crucial,	as	abstinence	rates	are	likely	
affected	 by	 neurochemical	 alterations	 that	 occur	 during	 withdrawal.	 Such	
alterations	include	changes	in	protein	expression	and	phosphorylation	state	of	 the	
NR2B	 subunit	 of	 the	 NMDA	 receptor.	 In	 fact,	 over‐activation	 of	 this	 subunit	 is	
thought	to	contribute	to	symptoms	associated	with	EWD.	EtOH	exposure	has	been	
found	to	elevate	levels	of	NR2B	mRNA	and/or	NR2B	subunit	protein,	although	these	
findings	are	not	consistent	(discussed	in	Prendergast	&	Mulholland,	2012).	Recently,	
increases	in	tyrosine	phosphorylation	of	the	subunit	were	found	following	IA	EtOH	
exposure	 in	 the	 dorsal	 striatum	 (Wang	 et	 al,	 2011),	 and	 models	 of	 forced	 EtOH	
exposure	 have	 revealed	 elevations	 in	 the	 hippocampus	 (Wu	 et	 al,	 2010).	
Additionally,	 there	 is	 a	 link	 between	 stress	 and	 NR2B	 activation,	 as	 elevations	 in	
CORT	lead	to	the	synthesis	and	release	of	polyamines,	which	allosterically	increase	
activity	at	the	NR2B	subunit.	Together,	 these	studies	provide	evidence	that	the	GR	
presents	 a	 likely	 target	 for	 both	 reducing	 EtOH	 consumption	 and	 promoting	
abstinence	by	decreasing	the	severity	and	consequences	of	EWD.		
	 Most	 preclinical	 investigations	 into	 the	 effects	 of	 AUDs	 use	 involuntary	
methods	 of	 EtOH	 delivery,	 as	 rodents	 do	 not	 readily	 self‐administer	 levels	 of	 the	
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drug	 sufficient	 to	 produce	 intoxication	 and	 dependence.	 However,	 there	 is	
accumulating	evidence	that	EtOH	promotes	behavioral	and	neurochemical	changes	
that	 are	 dependent	 upon	 voluntary	 EtOH	 consumption	 (Mitchell	 et	 al.,	 2012;	
Moolten	 &	 Kornetsky,	 1990;	 Pautassi,	 Truxell	 et	 al.,	 2008;	 Weise‐Kelly	 &	 Siegel,	
2001).	Data	 also	 suggest	 that	 individual	 differences	 in	HPA‐axis	 reactivity	 and	GR	
polymorphisms	 can,	 at	 least	 in	 part,	 mediate	 drinking	 behavior	 and	 the	
development	 of	 dependence	 (Desrivieres	 et	 al,	 2010).	 Therefore,	 using	 voluntary	
models	 of	 EtOH	exposure,	which	 allows	 for	 individual	 differences	 in	 consumption	
patterns	to	arise,	can	provide	insights	concerning	factors	that	contribute	to	AUDs.		
The	 following	 investigation	uses	a	voluntary	 intermittent	access	(IA)	model	
of	 EtOH	 exposure	 to	 investigate	 the	 interaction	 between	 CORT	 and	 consumption.	
We	sought	to	characterize	the	pattern	of	drinking	that	occurs	 in	this	model	and	to	
determine	 if	dependence	 is	produced	 following	7	weeks	of	exposure,	as	measured	
by	 alteration	 in	 the	 ASR	 during	 periods	 of	 acute	 (T1)	 and	 prolonged	 withdrawal	
from	 EtOH	 (T2).	 The	 expression	 and	 state	 of	 the	 NMDA	 NR2B	 receptor	 were	
assessed,	 as	 EtOH	 consumption,	 dependence,	 and	 withdrawal	 have	 been	 closely	
linked	 to	 this	 receptor	 protein.	 It	 was	 hypothesized	 that	 expression	 and	 tyrosine	
phosphorylation	of	the	NR2B	subunit	would	be	elevated	in	EtOH	exposed	animals.	
To	further	explore	the	 interaction	between	EtOH	and	CORT,	the	expression	of	GRs	
were	also	 evaluated;	 expression	was	expected	 to	 increase	during	protracted	EWD	
(T20).	 Immunoblotting	 for	 both	 proteins	was	 conducted	within	 the	 hippocampus	
and	prefrontal	cortex	at	the	conclusion	of	the	studies.	
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Materials	and	Methods	
	
Subjects	
Male,	 Long‐Evans	 rats	 (60	 days	 old;	 Harlan	 Laboratories,	 Indianapolis,	 IN)	
were	single	housed	and	exposed	to	12	hour	reversed	dark/light	cycle	(lights	off	at	
0900hrs).	 During	 a	 one	 week	 acclimation	 period,	 animals	 were	 handled	 for	
20min/day	for	3	days.	Animal	and	food	weights	were	taken	weekly	between	0800	
and	 0900hrs	 on	 Monday.	 Animals	 had	 ad	 libitum	 access	 to	 food	 and	 water	
throughout	the	experimental	procedure.		
	
Intermittent	Access	to	Ethanol		
Animals	 were	 given	 24hrs	 of	 concurrent	 access	 to	 1	 standard	 bottle	
containing	a	20%	(v/v)	EtOH/water	solution	and	one	standard	bottle	containing	tap	
water.	After	24hrs,	EtOH	bottles	were	 removed	and	all	 animals	 received	2	bottles	
containing	tap	water	(for	Experimental	Timeline,	see	Table	2.1).		Placement	of	EtOH	
and	water	bottles	were	alternated	 to	avoid	side	preference.	This	pattern	of	access	
(24hrs	with	EtOH	followed	by	24hrs	without	EtOH)	continued	for	45	days	(21	days	
of	 EtOH	 exposure	 on	 M‐W‐F).	 Two	 empty	 cages	 containing	 no	 animal	 received	
identical	 treatment	 regarding	 bottle	 changes	 and	 served	 to	 account	 for	 bottle	
leakage	 (leak	 controls).	 A	 separate	 group	 of	 animals	 (water	 controls)	 received	
identical	treatment	except	neither	bottle	contained	EtOH.	
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Table	2.1	Experimental	Timeline	
	
	 M	 T	 W	 TH	 F	 SA	 SU	
WK1	 							T0	
Baseline	ASR	
	 Blood	Draw	
EtOH/Water	
	
Water/Water	
	
EtOH/Water	
	
Water/Water	
	
	
WK2	 EtOH/Water	 Water/Water	 EtOH/Water	 Water/Water	 EtOH/Water	 Water/Water	 	
WK3	 EtOH/Water	 Water/Water	 EtOH/Water	 Water/Water	 EtOH/Water	 Water/Water	 	
WK4	 EtOH/Water	 Water/Water	 EtOH/Water	 Water/Water	 EtOH/Water	 Water/Water	 	
WK5	 EtOH/Water	 Water/Water	 Blood	Draw	
EtOH/Water	
Water/Water	 EtOH/Water	 Water/Water	 	
WK6	 EtOH/Water	 Water/Water	 EtOH/Water	 Water/Water	 EtOH/Water	 Water/Water	 	
WK7	 EtOH/Water	 Water/Water	 EtOH/Water	 Water/Water	 EtOH/Water	 Water/Water	 	
WK8	 	
EtOH/Water	
	
Water/Water	
T1	ASR	
Water/Water	
	
Water/Water	
	
Water/Water	
	
Water/Water	
	
	
WK9	 T2	ASR	
Sacrifice‐
Trunk	Blood		
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Measures	of	Ethanol	Consumption	
	 EtOH	 consumption	 was	 measured	 in	 two	 manners.	 First,	 bottles	 given	 to	
animals	(water	and	EtOH)	were	weighed	prior	to	presentation	and	again	following	
24hrs	 of	 access.	 This	 value,	 less	 the	 weight	 change	 detected	 in	 the	 leak	 control	
bottles,	was	expressed	as	mL/kg	of	 fluid	 intake.	Twenty	percent	of	 this	value	was	
multiplied	by	the	specific	gravity	of	200proof	EtOH	(0.794g/cm3)	to	determine	the	
EtOH	dose	(g/kg)	each	animal	consumed.	Additionally,	a	 subset	of	animals	 (n=12)	
were	video	 recorded	 for	24hrs	during	week	7	of	 the	 study.	Videos	were	 rated	 for	
drinking	behavior,	which	was	easily	identifiable.		Drinking	criteria	included	contact	
between	 the	 animals’	mouth	 and	 the	 bottle	 spout	 and	 both	 front	 feet	 leaving	 the	
cage	 floor.	 This	 measure	 yielded	 a	 pattern	 defining	 the	 times	 of	 day	 in	 which	
drinking	 occurred,	 number	 of	 drinking	 episodes	 per	 day,	 and	 time	 spent	 drinking	
per	episode.		
	
Blood	Ethanol	and	Corticosterone	Concentration	
Blood	was	collected	(approximately	140	µl/animal/time	point)	by	placing	a	
lateral	nick	in	the	tip	of	the	tail	prior	to	EtOH	exposure	and	again	1hr	following	the	
introduction	of	EtOH	during	week	5.	Six	days	following	the	removal	of	EtOH,	animals	
were	 euthanized	 via	 rapid	 decapitation	 and	 trunk	 blood	 was	 collected.	 Upon	
collection,	 blood	 samples	 were	 placed	 on	 ice	 and	 centrifuged	 (5	 min	 at	 15,000	
g/min);	blood	plasma	was	collected	and	immediately	stored	at	‐80°C.		
Blood	EtOH	levels	(BEL)	were	determined	using	the	Analox	AM1	instrument	
(Analox	Instruments,	Lunenburg,	MA),	which	measures	blood	EtOH	concentrations	
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indirectly	 through	 measurement	 of	 molecular	 oxygen	 levels.	 In	 the	 presence	 of	
molecular	 oxygen,	 EtOH	 is	 oxidized	 by	 the	 enzyme	 alcohol	 oxidase	 to	 form	
acetaldehyde	 and	 hydrogen	 peroxide.	 Under	 the	 conditions	 of	 the	 assay,	 oxygen	
consumption	is	directly	proportional	to	EtOH	concentration	in	the	plasma	sample.	
Blood	 CORT	 levels	 (BCLs)	 were	 determined	 using	 a	 competitive	 EIA	
Corticosterone	kit	(IDS	Limited,	Fountain	Hills,	AZ).	 	Briefly,	100	µl	of	each	diluted	
sample	(1:20),	calibrator,	and	control	and	100µl	of	enzyme	(corticosterone	labeled	
with	 horseradish	peroxidase)	were	 added	 to	 an	 antibody	 coated	plate	 (polyclonal	
rabbit	anti‐corticosterone)	in	duplicate	and	incubated	at	4°C	for	24	hrs.	 	Following	
incubation,	 the	 plate	 was	 thrice	 washed	 and	 200	 µl	 of	 substrate	
(tetramethylbenzidine	 and	 hydrogen	 peroxide)	 was	 added.	 	 After	 30	 min,	 stop	
solution	(0.5M	hydrochloric	acid)	was	added	and	 the	microplate	was	read	using	a	
Beckman	 Coulter	 DTX	 880	 Mulitmodal	 Detector	 (Lagerhausstrasse,	 Austria)	 with	
Beckman	 Coulter	 Multimode	 Detection	 Software	 (v.20.0.12).	 	 Mean	 absorbance	
values	for	samples,	controls,	and	calibrators	were	measured	at	450nm	producing	a	
mean	 value;	 this	 value	 was	 used	 to	 calculate	 percent	 binding	 (B/B0%=[(mean	
absorbance)/(mean	 absorbance	 for	 “0”	 calibrator)]×100).	 	 Mean	 concentration	 of	
CORT	 for	 each	 sample	 (ng/ml)	was	 determined	 based	 upon	 the	 calibration	 curve	
defined	by	known	samples	that	were	run	with	the	experimental	samples.		
	 	 	 	
Behavioral	Measures	
Acoustic	Startle	Reactivity	was	measured	in	a	commercially	available	startle	
system	(S‐R	Lab,	San	Diego,	CA,	USA).	Chambers	(35x33x38.5	cm,	 length	x	width	x	
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height)	contained	an	overhead	 light	 (3	 lux)	and	a	Plexiglas	holding	tube	(8.9cm	in	
diameter	x	20.3cm	in	length),	in	which	animals	were	placed	for	testing.	The	holding	
tube	was	designed	to	reduce	but	not	eliminate	voluntary	movement	of	the	animal,	
thereby	reducing	stress.	A	piezoelectric	accelerometer	within	each	tube	transduced	
large	movement	by	the	animal	and	was	attached	to	a	PC,	on	which	responses	were	
recorded	 using	 S‐R	 Lab	 software	 (v5.0).	 A	 speaker	 located	 in	 the	 ceiling	 of	 the	
chamber	delivered	acoustic	startle	stimuli	as	well	as	75dB	white	noise	background.	
At	 the	 beginning	 of	 each	 trial	 (defined	 below),	 data	were	 recorded	 over	 a	 100ms	
window	and	were	 sampled	 at	 1ms	 intervals.	 Data	were	 recorded	 in	 two	different	
chambers.	 Both	 input	 (dB)	 and	 output	 (amplitude	 of	 response)	 were	 calibrated	
prior	to	each	testing	session	using	San	Diego	Instruments	calibration	devices.		
		Data	 consisted	 of	 two	 measures,	 startle	 reactivity	 (first	 startle	 response	
(FSR))	 and	 startle	 plasticity	 (habituation	 of	 the	 startle	 response	 and	 prepulse	
inhibition).	 ASR	 data	was	 collected	 prior	 to	 EtOH	 exposure	 (T0)	 and	 again	 26hrs	
(T1)	and	6	days	(T2)	after	EtOH	exposed	animals	received	the	final	EtOH	exposure.	
These	 time	 points	 were	 chosen	 to	 reflect	 both	 acute	 and	 protracted	 EWD	 in	 the	
EtOH	exposed	animals.	During	IA	access,	EtOH	exposed	animals	become	accustomed	
to	 experiencing	 24hrs	 between	 EtOH	 exposures.	 Therefore,	 at	 26hrs	 (T1),	 it	 was	
reasoned	that	animals	would	have	expected,	but	not	received	EtOH,	a	situation	that	
would	elevate	anxiety	in	dependent	animals.		
Prior	to	all	ASR	testing	a	5	min	acclimation	period	consisting	of	background	
noise	 (75dB	white	noise)	was	presented	and	remained	on	 throughout	 testing.	For	
measures	 of	 FSR	 and	 habituation,	 animals	 were	 presented	 with	 6	 120dB	 stimuli	
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(Sandbak	et	al,	2000).	The	FSR	is	equivalent	to	the	amplitude	of	the	startle	response	
to	 the	 initial	 presentation	 of	 a	 120dB	 stimulus	 tone.	 Habituation	 score	 was	
calculated	by	subtracting	the	average	amplitude	of	 the	 last	 three	startle	responses	
from	 the	 average	 of	 the	 initial	 three	 responses.	 Prepulse	 inhibition	 (PPI)	 was	
assessed	over	8	blocks	consisting	of	a	random	presentation	of	the	following	5	trials:																								
			 	 (i)			Pulse	stimulus	(110	dB	for	40ms)		
			 	 (ii)		Prepulse	A(4dB	for	20ms)	+	pulse	stimulus	
			 	 (iii)	Prepulse	B(8dB	for	20ms)	+	pulse	stimulus	
			 	 (iv)	Prepulse	C(16dB	for	20ms)	+	pulse	stimulus	
			 	 (v)	No	stimulus	(background	noise	was	applied)	
	
PPI	 was	 defined	 as	 a	 decrease	 in	 the	 amplitude	 of	 the	 startle	 response	 in	 the	
presence	of	the	prepulse	stimuli	and	expressed	as:	PPI	=	(100‐(mean	startle	reflex	
with	 the	 prepulse/mean	 startle	 reflex	 without	 prepulse))	 x	 100	 (Geyer,	 2001).	
Interval	between	the	presentation	of	 the	prepulse	and	pulse	was	100ms,	 intertrial	
intervals	 were	 varied	 randomly	 in	 the	 range	 of	 10	 to	 30s.	 Total	 time	 in	 startle	
chamber	for	each	animal	was	approximately	25	minutes.		
	
Protein	Expression	
Following	 rapid	decapitation,	whole	brains	were	 removed	 from	a	 subset	of	
animals.	 Olfactory	 bulbs	 were	 discarded	 and	 prefrontal	 cortex	 was	 isolated	 from	
each	hemisphere;	following	sagittal	section,	hippocampi	were	bi‐laterally	removed.	
Tissue	from	each	brain	region	was	placed	on	dry	ice	immediately	following	removal	
and	 stored	 at	 ‐80°C.	 Frozen	 tissue	 was	 placed	 in	 lysis	 buffer	 ((Radio‐
Immunoprecipation	 Assay	 (RIPA)	 Buffer	 (1:100;	 Thermo	 Scientific,	 Rockford	 IL),	
99.8M‐6	PMSF/EtOH	in	PBS	(1:100),	HALT	Protease	&	Phosphotase	Inhibitor	(1:10;	
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Thermo	 Scientific,	 Rockford	 IL)).	 Tissue	 was	 coarsely	 ground	 using	 a	 pestle	 and	
centrifuged	at	4°C	for	20min	at	12000rpm.	Subsequently,	supernatant	was	collected	
and	 assayed	 using	 the	 Pierce®	 BCS	 Protein	 Assay	 Kit	 (Fisher)	 to	 determine	 the	
protein	concentration	of	each	sample.		
Immunoblotting	 was	 conducted	 in	 the	 Mini‐Protean®	 System	 using	 TGX	
Gradient	Precast	Gels	(4‐15%)	(Bio‐Rad,	USA).	Prepared	samples	(10uL	containing	
50ug	of	protein)	or	Bio‐Rad	Precision	Plus	Protein™	standards	(7uL)	were	vortexed	
and	 loaded	 into	 lanes.	 Samples	 were	 electrophoresed	 in	 1x	 Tris/glycine/sodium	
dodecyl	 sulfate	 buffer	 (Bio‐Rad,	 Hercules,	 CA,	 USA)	 at	 room	 temperature	 for	
approximately	 2.5	 hrs	 at	 80‐90V.	 Protein	 was	 transferred	 onto	 a	 membrane	
(nitrocellulose	paper)	in	buffer	(.25M‐3	Tris	Base,	.19M‐3	Glycine,	10%Methanol)	for	
1hr	 at	 100V,	 carriage	 was	 chilled	 by	 the	 addition	 of	 an	 ice	 pack.	 Membrane	was	
removed	and	 rinsed	 twice	 in	1xTBS	and	allowed	 to	 rock	at	 room	 temperature	 for	
15min.	Membrane	was	removed	and	rinsed	twice	in	1xTBS	and	agitated	in	blocking	
agent	(5%	non‐fat	dried	milk	in	TBS)	for	1hr	at	room	temperature.	Membrane	was	
rinsed	in	1xTBS	with	the	addition	of	10%	Tween20	(TTBS)	then	agitated	in	TTBS	for	
15min.	Following	a	final	rinse,	membrane	was	placed	in	primary	antibody	solution	
(5%	non‐fat	dried	milk	or	bovine	serum	albumin	in	TTBS	with	anti‐NR2B	(1:1000;	
Millipore),	‐GR	(1:5000;	Santa	Cruz),	or	‐pNR2B	(1:500;	Cell	Signaling)	and	agitated	
overnight	at	4°C.	On	day	2,	membranes	were	rinsed	and	agitated	 in	TTBS	 in	5min	
intervals	for	a	total	of	20min.	Following	placement	in	light‐proof	boxes,	membranes	
were	 agitated	 in	 fluorescent	 secondary	 anti‐body	 solution	 (5%	milk	 in	TTBS	with	
IRDye800	 (Rockland	 Immunochemicals,	 Gilbertsville,	 PA,	 USA)	 for	 1hr	 at	 room	
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temperature.	Following	three	5min	rinse/agitation	cycles	in	TTBS,	membranes	were	
imaged	on	Odyssey	Infrared	Imaging	System	(LI‐COR	Biosciences,	Lincoln,	NE,	USA)	
and	quantified	using	Image	J	software	(NIH).		
	
Statistical	Analysis	
	 All	 data	 were	 analyzed	 using	 either	 mixed	 or	 repeated	 measure	 ANOVA.	
When	appropriate,	treatment	was	used	as	the	between	subjects	and	time	(week	or	
timepoint)	 as	 within	 subjects	 factors.	 Correlations	 were	 determined	 using	
Pearsons’s	 r.	 When	 appropriate,	 post	 hoc	 testing	 utilized	 Bonferroni	 t‐test.	
Significance	was	determined	at	p	<	0.05.	
	
Results	
Body	Weight	and	Food	Consumption		
	 Body	 and	 food	 weights	 were	 taken	 weekly	 on	 Monday	 prior	 to	 the	
introduction	of	EtOH	and	 continued	 through	Monday	of	week	7.	 	Weights	did	not	
differ	 significantly	 between	 EtOH	 exposed	 (n=24)	 and	water	 control	 (n=8)	 group	
prior	to	experimentation.	Analysis	of	weekly	weight	gain	during	the	study	revealed	
no	interaction	or	main	effect	of	treatment	(final	weights	(g):	EtOH=	425	±35.6,	Ctrl	=	
415	±30.1),	but	a	main	effect	of	time	(F(6,180)	=	52.13	(6,	180)	p<	0.001)	occurred.	
Similarly,	analysis	of	food	consumption	revealed	no	significant	difference	in	weekly	
food	 intake	 between	 the	 groups	 (total	 food	 intake	 (g):	 EtOH	 =	 1119	 ±67.1,	 Ctrl	 =	
1150	±83.4),	but	a	main	effect	of	time	was	observed	(F(6,180)=6.28	p	<	0.001),	with	
a	significant	elevation	in	food	consumption	occurring	during	week	7	(fig.	2.1).	
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Fig	 2.1.	 Weekly	 food	 consumption	 and	 weight	 gain	 during	 weeks	 1‐7.	 No	 differences	
were	found	between	EtOH	(n=24)	and	control	animals	(n=8)	for	either	variable.	Gradual	
increases	in	food	consumption	were	accompanied	by	gradual	but	significant	increases	in	
weight.	 Average	 food	 consumption	 (g)=	 160.9	 ±2.97;	 average	weight	 gain	 (g)	 =	 231.1	
±11.95.	(*=	as	compared	to	week	1,	p	<	0.05;	**=as	compared	to	weeks	1‐4,	p	<	0.05.) 
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Ethanol	Consumption	and	Blood	Ethanol	Concentration	
	 Total	 fluid	 consumption	 (calculated	 as:	 total	 volume	 of	 EtOH	 (ml/kg)	 plus	
total	volume	of	water	(ml/kg))	for	EtOH	exposed	animals	(n=24)	was	compared	to	
total	 consumption	 of	water	 treated	 controls	 in	 a	 two‐way	mixed	measure	ANOVA	
(treatment	x	time	(week))	revealed	a	significant	 interaction	(F(6,180)	=	4.475,	p	<	
0.001).	 Water	 control	 animals	 consumed	 significantly	 more	 fluid	 than	 did	 EtOH	
treated	animals	during	weeks	1	and	2,	after	which	total	fluid	consumptions	between	
the	groups	did	not	differ	significantly	(fig	2.2).		
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Figure	 2.2.	 Total	 fluid	 consumed	 by	 water	 control	 (n=8)	 and	 EtOH	 exposed	 (n=24)	
animals.	During	weeks	1	and	2,	water	control	animals	consumed	significantly	more	fluid	
than	did	EtOH	exposed	animals,	no	significant	difference	was	found	during	later	weeks.	
(*	=	as	compared	to	water	controls,	p	<	0.001) 
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To	analyze	the	consumption	pattern	within	the	EtOH	treated	animals,	a	two‐
way	 repeated	 measure	 ANOVA	 (fluid	 type	 (EtOH	 or	 water)	 x	 time	 (week))	 was	
conducted.	 Analysis	 revealed	 a	 significant	 interaction	 between	 the	 type	 of	 fluid	
consumed	 and	 time	 (F(6,	 138)=	 8.63,	 p	 <	 0.001).	 Water	 consumption	 in	 these	
animals	 declined	 significantly	 between	 week	 3	 and	 5,	 stabilizing	 thereafter	 (fig	
2.3a).	EtOH	consumption	elevated	during	the	first	three	weeks	of	exposure,	followed	
by	 a	 decline	 during	week	 four	 (the	 8th	 EtOH	 exposure)	 where	 it	 remained	 stable	
until	week	seven	(fig	2.3a).	Additionally,	EtOH	consumption	was	significantly	lower	
than	 that	 of	 water	 during	 all	 weeks,	 except	 in	 weeks	 5	 and	 7,	 when	 water	
consumption	 decreased.	 Figure	 2.4a	 depicts	 the	 concentration	 of	 EtOH	 (g/kg)	
animals	 consumed,	 on	 average,	 during	 a	 24hr	 period	 of	 exposure	 (average	 dose	
(g/kg/24hr)	 3.79,	 ±	 0.43).	 Blood	 EtOH	 concentrations	 resulting	 from	 these	 doses	
ranged	from	6.3	‐	116.9	mg/dl,	and	the	average	BEC	obtained	was	42.0,	±7.6	mg/dl	
(fig	2.4b). 	
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Fig	2.3a.	 Fluid	 consumption	 in	 animals	 given	 intermittent	 access	 to	20%	EtOH.	Animals	
consumed	 more	 water	 than	 EtOH	 during	 all	 but	 weeks	 5	 and	 7.	 Average	 consumption	
(ml/kg):	water	=	44.3,	±1.90;	EtOH	=	25.2,	±2.94.	(*=as	compared	to	water	control	animals,	
p	<0.05;	#=as	compared	to	week	1,	p	<	0.05)
* 
*
*#
* *
#
#
#
# 
36	
	
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	‐
	1.00
	2.00
	3.00
	4.00
	5.00
	6.00
	7.00
1 2 3 4 5 6 7
Et
O
H
	(
g/
kg
)
Drinking	Week
Figure	2.3b.
*
Fig	2.3b.	Average	weekly	dose	of	EtOH	was	stable	between	weeks	1and	2.	Consumption	
increased	during	week	3,	and	remained	steady	during	weeks	4‐7.	Average	weekly	dose	of	
EtOH	(g/kg)	=	3.79	±0.43.	(p	<0.05;	*=as	compared	to	week	1,	p	<	0.05) 
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Figure	2.4a.
Distribution	of	EtOH	Consumption
Fig	 2.4a.	 Distribution	 of	 the	 average	 EtOH	 dose	 (g/kg/exposure)	 (n=24)	 given	
intermittent	access	to	20%	EtOH.	IA	model	produced	a	wide	array	of	EtOH	consumption,	
ranging	 from	 2.0‐	 6.7g/kg/exposure,	 with	 the	 average	 animal	 self‐administering	 3.79	
±0.28	g/kg/exposure. 
Distribution	of	BEC 
Following	1Hr	of	EtOH	Access 
Fig	 2.4b.	 Distribution	 of	 the	 average	 blood	 EtOH	 concentration	 (mg/dl)	 in	 animals	
(n=24)	 given	 intermittent	 access	 to	 20%	 EtOH.	 IA	model	 produced	 a	 wide	 array	 of	
BECs	following	1Hr	of	EtOH	access,	ranging	from	6.3‐116.9	mg/dl	and	averaged	42.0,	
±7.1	mg/dl	(b). 
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Analysis	 of	 video	 data	 revealed	 that	 animals	 engaged	 in	 EtOH	 drinking	 on	
average	7.6	times	per	day,	spending	an	average	of	~56sec	of	drinking	per	visit.	The	
majority	 of	 drinking	 (82.6%)	 occurred	 during	 the	 dark	 cycle	 (0900‐2000hrs)	
(drinking	time	(min):	total=83.8;	dark	cycle=	69.3;	light	cycle	=14.6),	with	23.3%	of	
all	 drinking	 taking	 place	 within	 the	 first	 4hrs	 of	 exposure.	 The	 30min	 following	
1130hr	was	the	most	active	time	for	EtOH	consumption	(8	of	12	animals	consumed	
EtOH	at	 this	 time	point	 for	 a	 total	 of	 10.1min).	Overall,	 drinking	behavior	did	not	
remain	 consistent	 during	 the	 dark	 cycle	 but	 rather	 periods	 of	 elevated	 drinking	
were	followed	by	periods	of	reduced	drinking	(fig	2.5).		
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Fig	2.5.	 	Drinking	behavior	recorded	during	a	24hr	period	of	exposure	to	20%	EtOH,	
data	for	each	animal	(n=12)	is	represented	by	a	different	color,	the	length	of	the	bar	is	
indicative	 of	 the	 total	 time	 spent	 drinking	 at	 each	 visit	 to	 the	 EtOH	 bottle.	 Animals	
spent	a	greater	amount	of	time	drinking	during	the	dark	cycle	(82.6%	of	total	time),	
with	 23.3%	 of	 all	 drinking	 taking	 place	 during	 the	 initial	 4hrs	 of	 exposure	 (09:00‐
12:00).	A	spike	in	consumption	occurred	just	prior	to	and	after	lights	were	turned	on	
at	 21:00hrs.	 72	visits	 to	EtOH	bottles	were	 recorded	during	 the	dark	 cycle,	with	 an	
average	 of	 57.8	 sec	 spent	 drinking	 per	 visit.	 This	 is	 compared	 to	 18	 visits	 (48.5	
sec/visit),	which	occurred	during	 the	 light	 cycle.	Animals	 engaged	 in	 a	 total	 of	 83.8	
min	of	drinking,	90	individual	visits	were	recorded	during	the	24hr	period.	 
40	
	
Corticosterone	Analysis	
	 Data	from	one	EtOH	animal	was	excluded	from	this	analysis,	as	the	quantity	
of	plasma	remaining	after	the	determination	of	BEC	was	insufficient	to	conduct	the	
CORT	 assay	 (EtOH	 n=23,	 control	 n=8).	 Further,	 CORT	 data	 collected	 at	 the	 final	
timepoint	 (T2)	 represents	a	 subset	of	 animals.	Due	 to	procedural	 issues,	one	data	
point	 (control	 animal)	 from	 this	 subset	was	 excluded	 from	 analysis	 (EtOH	n=	 12;	
control	n=	3).	Due	to	the	reduced	number	of	control	subjects	represented	at	the	final	
timepoint,	statistical	analysis	was	not	performed.	Average	and	SEM	were	calculated	
for	 each	 group	 at	 each	 timepoint	 (T0,	 following	 1	 hr	 of	 EtOH	 exposure,	 and	 T2),	
these	 values	 are	 represented	 in	 fig	 2.6a.	 Plasma	 CORT	 concentration	 in	 both	 the	
water	control	animals	and	EtOH	exposed	animals	were	elevated	at	T2,	just	prior	to	
sacrifice.	
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Figure	2.6a.	Plasma	CORT	levels	recorded	at	baseline	(T0),	1hr	following	exposure	to	20%	
EtOH,	 and	 prior	 to	 sacrifice	 (T2).	 Plasma	 CORT	 levels	 are	 elevated	 in	 EtOH	 exposed	
animals	at	the	final	time	point.	Data	were	not	subjected	to	statistical	analysis. 
n=23 n=23	 n=12n=8	 n=8 n=3
Fig.	2.6a.	
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Further	analysis	of	CORT	levels	within	EtOH	treated	animals	yielded	several	
significant	 correlations	 relative	 to	 EtOH	 consumption.	 First,	 EtOH	 consumption	
(g/kg/24hr)	 was	 positively	 correlated	 with	 baseline	 (T0)	 CORT	 values	
(r(21)=0.543,	p=0.0074),	suggesting	that	CORT	levels	are	predictive	of	subsequent	
drinking	behavior	 (fig	2.6b).	A	positive	 correlation	was	also	 found	between	CORT	
levels	 following	1hr	of	EtOH	exposure	and	blood	EtOH	 level	 assessed	at	 the	 same	
time	 point	 (r(21)=0.418,	 p=.0419)	 (fig	 2.6c).	 Finally,	 CORT	 levels	 taken	 following	
1hr	 of	 EtOH	 exposure	 were	 positively	 correlated	 with	 samples	 taken	 following	 6	
days	of	EWD	(T2),		immediately	prior	to	sacrifice	(r(21)=0.646,	p=0.0234)	(fig	2.6d).	
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Figure	 2.6b.	 Plasma	 CORT	 concentration	 prior	 to	 (T0)	 and	 following	 1Hr	 of	 EtOH	
exposure.	 Animals	 with	 higher	 levels	 of	 plasma	 CORT	 prior	 to	 EtOH	 exposure	
consumed	significantly	higher	levels	of	20%	EtOH. 
Figure	 2.6c.	 Plasma	 CORT	 concentration	 following	 1Hr	 of	 EtOH	 exposure	 is	
associated	with	BEC	at	the	same	time	point.	 
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Figure	2.6d.	Plasma	CORT	levels	following	1Hr	of	EtOH	exposure	and	following	6	days	
of	EWD	(T2).	A	significant	correlation	between	CORT	levels	assessed	following	6	days	
of	EWD	and	levels	measured	following	1hr	of	EtOH	exposure	were	found.			 
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Acoustic	Startle	Reflex	
	 Data	from	four	animals	were	excluded	from	startle	analysis.	Startle	reactivity	
for	these	animals	was	assessed	in	a	first	generation	ASR	chamber.	Upon	analysis	it	
was	observed	that	animals	evaluated	in	these	chambers	had	greater	within	session	
response	 variability	 and	 that,	 on	 average,	 responses	 were	 greater	 than	 animals	
assessed	 in	 the	 newer	model	 chambers.	 Personal	 communication	with	 San	 Diego	
Instruments	 verified	 that	 chambers	 of	 this	 age	 were	 susceptible	 to	 producing	
unreliable	 results	 and	 therefore,	 data	 collected	 in	 these	 chambers	 were	 excluded	
from	 analysis.	 Additionally,	 the	 data	 detailed	 below	 include	 values	 of	 three	water	
treated	control	animals	that	were	collected	in	a	separate	pilot	study.	These	animals	
were	exposed	 to	 the	same	experimental	conditions	described	above.	EtOH	treated	
animals	 from	this	pilot	study	were	excluded	from	analysis,	as	methods	concerning	
EtOH	 exposure	 were	 not	 deemed	 consistent	 with	 those	 detailed	 herein	 (for	 ASR	
data:	EtOH	n=21;	Ctrl	n=10).	
	 FSR	(fig	2.7):	 A	significant	interaction	was	found	between	treatment	and	day	
(F(2,58)=	 3.49,	 p	 =	 0.037).	 	 Water	 treated	 control	 animals	 demonstrated	 no	
elevation	in	FSR	at	either	T1	or	T2,	as	compared	to	baseline	value	(T0).	However,	a	
similar	 comparison	 to	 baseline	 (T0)	 value	 revealed	 that	 EtOH	 treated	 animals	
displayed	an	elevated	startle	response	following	26hrs	(T1)	and	6	days	of	EWD	(T2).	
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n=10 n=21 Figure	2.7.	Magnitude	of	 the	startle	reflex	to	the	first	presentation	of	a	120dB	pulse	as	
measured	at	baseline	 (T0),	26hrs	 (T1)	and	6days	 (T2)	 following	EtOH	withdrawal.	No	
differences	were	 detected	 among	 the	water	 control	 animals.	 Animals	 exposed	 to	 20%	
EtOH	 had	 significantly	 higher	 response	 during	 both	 acute	 (T1)	 and	 protracted	 (T0)	
withdrawal.	(*=		compared	to	T0,	p	<	0.05) 
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Habituation	 (fig	 2.8):	 	Data	 regarding	 the	 ability	 of	 animals	 to	 habituate	 to	
repeated	presentations	of	a	startling	pulse	(120dB)	revealed	no	effect	of	treatment,	
but	 a	main	 effect	 of	 timepoint	 (F(2,58)	 =	 6.79,	 p=0.002)	was	 significant.	 Post	 hoc	
testing	 revealed	 a	 significant	 difference	 between	 habituation	 at	 baseline	 as	
compared	to	values	measured	following	26hrs	(T1)	or	6	days	(T2)	of	EWD.	A	virtual	
lack	of	 habituation	was	observed	during	baseline	 evaluation,	whereas	habituation	
was	observed	at	 later	time	points	(M	(arbitrary	units):	baseline	(T0)	=	‐0.8,	±9.13;	
26hrs	EWD	=	33.9,	±9.13;	6	days	=	28.3,	±9.13).	
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Figure	 2.8.	 	 Habituation	 to	 the	 repeated	 presentation	 of	 a	 120dB	 pulse	 (n=31,	 all	 time	
points).	No	differences	were	 found	 regarding	 treatment.	Habituation	was	 evident	 at	 the	
latter	 two	 time	 points	 measured,	 although	 animals	 showed	 virtually	 no	 habituation	 at	
baseline	(T0).	(*=		compared	to	T0,	p	<	0.05) 
Figure	2.8.	
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PPI	(fig	2.9a	&	b):	 PPI	 data	 was	 initially	 analyzed	 for	 treatment	 effects	
within	 each	 level	 of	 the	 prepulse	 (treatment	 (2)	 x	 level	 (3)).	 As	 no	 effects	 of	
treatment	were	found,	data	were	collapsed	across	the	variable	and	a	repeated	two‐
way	ANOVA	(timepoint	(3)	x	level	(3))	was	conducted.		
A	main	effect	of	timepoint	(F(2,	60)	=	33.00,	p	<	0.001)	and	level	(F(2,	60)	=	
14.522,	p	<	0.001)	was	 found.	 Inhibition	of	 startle	 in	 the	presence	of	 the	prepulse	
was	 lowest	 at	 T0	 and	 improved	 at	 both	 subsequent	 timepoints	 (baeline	 vs	 26hrs	
EWD,	 p	 <	 0.001;	 BL	 vs	 6	 day	 EWD,	 p	 <	 0.001)	 (fig	 9a).	 Regarding	 the	 levels	 of	
prepulse,	the	highest	decibel	prepulse	(87dB)	produced	the	largest	inhibition	(79dB	
vs	 89dB;	 83dB	 vs	 89dB)	with	 no	 significant	 difference	 between	 the	 79	 and	 82dB	
prepulse	(9b).				
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Fig	2.9a.	Percent	of	Prepulse	inhibition	(PPI)	is	the	ability	of	animals	(n=31)	to	inhibit	the	
startle	 response	 to	a	pulse	 (12dB)	when	 the	pulse	 is	preceded	by	a	non‐startling	 level	of	
prepulse.		No	differences	were	found	regarding	treatment,	data	were	collapse	to	analyze	for	
the	effect	of	timepoint	and	level	of	prepulse	(79dB,	82dB,	87dB).	At	T0a	40%	reduction	in	
the	 startle	 response	 was	 observed,	 whereas	 reductions	 of	 ~65%	 were	 seen	 at	 later	
timepoints	(*	=	as	compared	to	T0,	p<	0.05)
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Fig	 2.9b.	 Inhibition	 of	 the	 prepulse	 was	 most	 robust	 at	 the	 highest	 level	 (87dB)	 of	
prepulse.	No	effect	of	EtOH	treatment	was	observed.	(**=	as	compared	to	79	and	82dB	
level	prepulse,	p	<	0.05). 
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Protein	Analysis	
	 Due	to	procedural	issues,	tissue	from	one	EtOH	treated	animal	was	excluded	
from	 analysis	 (EtOH	 n=11;	 Ctrl	 n=4).	 A	 one‐way	 ANOVA	 was	 used	 to	 analyze	
treatment	effects	in	protein	receptor	expression	of	NR2B	subunits	and	GR,	as	well	as	
changes	in	phosphorylation	state	of	the	NR2B	subunit.	Immunoblotting	experiments	
using	 the	 pNR2B	 antibody	 failed	 to	 produce	 measurable	 results.	 Communication	
with	 Cell	 Signaling	 determined	 that	 the	 antibody	 was	 ineffective	 at	 targeting	 the	
protein.	 Replacement	 antibody	 was	 subsequently	 delivered	 and	 verified	 to	 be	
functional,	 however,	 time	 restraints	 did	 not	 allow	 for	 re‐analysis	 of	 protein.	 No	
effect	 was	 found	 regarding	 EtOH	 induced	 changes	 in	 NR2B	 or	 GR.	 However,	 it	
should	 be	 noted	 that	 effects	 regarding	 changes	 in	 GR	 expression	 did	 approach	
significance	 (F=(1,14)=4.015,	 p	 =	 0.065)	 (mean	 arbitrary	 units)	 (EtOH=	 4260.8	
±481.1	vs	Ctrl	=	2680.1	±473.6).	Power	analysis	revealed	the	performed	test	(0.354)	
was	below	the	desired	power	of	0.800	due	to	the	low	sample	size	(EtOH	n=	12;	Ctrl	
n=4).	
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Discussion	
Characterization	of	Drinking	in	the	Intermittent	Access	Model	of	Ethanol	Exposure		
The	 current	 study	 sought	 to	 characterize	 voluntary	 drinking	 produced	 by	
intermittent	 access	 to	 20%	 EtOH,	 and	 the	 results	 yielded	 several	 interesting	
findings.	 	 Figure	1	demonstrates	 that	no	differences	 in	weight	gain	or	 food	 intake	
were	 observed	 between	 EtOH	 exposed	 and	 water	 treated	 animals	 during	 the	 7	
weeks	 of	 experimentation.	 In	 models	 of	 forced	 EtOH	 exposure	 (e.g.,	 single‐bottle	
choice,	intra‐gastric	gavage,	vapor	chamber	exposure)	weight	loss	is	typical	and	can	
be	problematic	when	 interpreting	data,	as	body	weight	 loss	can	be	an	 indicator	of	
adverse	health.	As	normal	weight	 gain	and	appetite	were	observed	 in	 the	present	
study,	 this	 extraneous	 variable	 does	 not	 need	 consideration	 when	 using	 this	
exposure	paradigm.		
A	difference	was	observed	when	comparing	total	fluid	intake	between	EtOH	
exposed	 and	water	 control	 animals,	 with	 water	 control	 animals	 consuming	more	
fluids	during	the	first	two	weeks	of	the	study	(fig	2.2).	However,	no	differences	were	
observed	 following	 week	 3,	 as	 total	 fluid	 consumption	 in	 both	 groups	 declined,	
remaining	 steady	 following	 week	 4.	 A	 broad	 distribution	 of	 EtOH	 consumption	
levels	 was	 observed,	 ranging	 from	 2.0‐6.3	 g/kg/exposure,	 with	 an	 average	
consumption	of	3.79	±0.43	(fig	2.	4a).	In	humans,	this	equates	to	approximately	3‐10	
drinks	in	a	male	and	4‐11	drinks	in	a	female	(average	weight	of	the	American	adult	
(kg):	male	88,	female=	75.4	(Fryar	et	al,	2012).	These	levels	of	consumption	reflect	
moderate	 (3	 drinks/day)	 to	 problem	 drinking	 (>	 3	 drinks/day)	 in	 the	 human	
population	 (NIAAA)	 and	 suggest	 the	 data	 collected	 in	 these	 experiments	 can	 be	
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generalized	 to	 individuals	 in	 these	 groups.	 Similarly,	 BEC	 data	 reported	 here	 are	
also	widely	distributed,	ranging	from	6.3	–	116.9mg/dl	(fig	2.4b).	However,	it	should	
be	noted	that	blood	samples	for	BEC	analysis	were	collected	following	1hr	of	EtOH	
exposure,	at	1000hrs,	while	the	most	robust	period	of	drinking	didn’t	occur	until	the	
30	minutes	between	1130	and	1200hrs	(fig	5).	Therefore,	while	data	reveal	the	wide	
range	of	BECs	produced	by	 the	model,	 the	data	are	 less	 likely	 to	reflect	maximum	
levels	that	resulted.		
	
Corticosterone	
These	studies	sought	to	investigate	the	relationship	between	CORT	and	EtOH	
consumption	and	revealed	several	associations	between	the	variables.	Perhaps	the	
most	revealing	finding	was	that	basal	levels	of	CORT	were	predictive	of	subsequent	
EtOH	consumption.	 Similarly,	Prasad	&	Prasad	 (1995)	 compared	 the	drinking	and	
HPA‐axis	profiles	of	selectively	bred	alcohol	preferring	(P)	and	non‐preferring	(NP)	
rats	 to	 that	 of	 the	 Holtzman	 Sprague‐Dawley	 rats,	 which	 are	 selectively	 bred	 for	
their	 CORT	 profile.	 Specifically,	 the	 profile	 of	 the	 high‐low	 (H‐L)	 animal	 is	 one	 of	
high	basal	secretion	and	low	stimulation	upon	fasting	(24hrs),	whereas	the	low‐high	
(L‐H)	animal’s	profile	is	reversed	with	low	basal	levels	and	a	high	fasting	response.		
The	researchers	found	both	drinking	and	CORT	profiles	between	the	animals	to	be	
similar,	such	that	the	P	and	H‐L	rats	both	display	elevated	levels	of	consumption	and	
baseline	 CORT	 levels.	 Similarly,	 the	 alcohol	 preferring	 AA	 rat	 displays	 elevated	
baseline	 CORT	 levels	 as	 compared	 to	 its	 non‐drinking	 counterpart,	 the	 ANA	 rat.	
Interestingly,	 this	 situation	 is	 reversed	 if	 the	 animals	 are	 group	 housed	 (Apter	 &	
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Eriksson,	 2005).	 The	 current	 findings	 are	 consistent	 with	 these	 data	 and	 suggest	
that	 elevated	 levels	 of	 CORT	 tend	 to	 be	 associated	 with	 increased	 EtOH	
consumption.		Together,	they	suggest	that	basal	CORT	levels	may	provide	a	valuable	
biomarker	for	EtOH	preference	that	and	that	this	trait	may	be	genetically	conferred.		
In	 humans,	 elevated	 baseline	 plasma	 cortisol	 is	 often	 found	 in	 alcohol	
dependent	 but	 abstinent	 individuals,	 while	 both	 blunted	 and	 elevated	 HPA‐axis	
reactivity	to	stressors	has	been	observed.	However,	lowered	basal	levels	of	cortisol	
and	ACTH	have	been	recorded	in	offspring	of	alcoholics.	These	somewhat	conflicted	
studies	 demonstrate	 that	 measuring	 one	 hormone	 level,	 whether	 basal	 or	 under	
stress,	 only	 provide	 a	 glimpse	 of	 the	 total	 HPA‐axis	 profile.	 A	 host	 of	 factors	
including	 receptor	 sensitivity	 and	 the	 influence	 of	 other	 hormones	 (i.e.,	 CRH	 and	
ACTH)	 need	 to	 be	 considered	 when	 contemplating	 the	 system.	 In	 addition,	 the	
importance	 of	 individual	 differences	 in	 HPA‐axis	 sensitivity	 and	 reactivity	 is	
becoming	increasingly	evident.	For	example,	Kerns	et	al.	(2005)	recently	identified	
an	 array	 of	 genes	 within	 the	 limbic	 system	 that	 were	 responsive	 to	 the	 acute	
administration	 of	 EtOH	 (e.g.,	 single	 i.p.	 dose	 of	 0.5‐2.0	 g/kg).	 Among	 these	 were	
glucocorticoid‐responsive	 genes	 that	 are	 differentially	 expressed	 in	mouse	 strains	
(DBA2/J	and	C57BL/6)	based	upon	EtOH	preference	and	sensitivity	(i.e.,	locomotor	
activation	and	sensitization)	(Costin	et	al.,	2013).	Exploring	how	these	genes	confer	
different	properties	regarding	acute	EtOH	exposure	could	provide	insight	into	why	
some	 individuals	 escalate	 from	 casual	 drinking	 to	 alcoholism	 and	 perhaps	 yield	 a	
molecular	 target	 for	 its	 treatment.	Providing	a	different	perspective	on	 the	 role	of	
glucocorticoids	 as	 they	 pertain	 to	 addiction,	 a	 recent	 review	 by	 Bartlett	 and	
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colleagues	 (Srinivasan	 et	 al.,	 2013)	 explored	 the	 possible	 protective	 effects	 of	 the	
hormone.	 These	 authors	 point	 out	 that	 the	 ability	 to	 persevere	 under	 stress	 (i.e.	
resilience),	 whether	 conferred	 via	 genetics	 or	 the	 environment	 (i.e.,	 learned),	
predicts	 resilience	 to	 the	 development	 of	 EtOH	 dependence.	 They	 also	 suggest	
cellular	mechanisms	by	which	glucocorticoids	may	mediate	this	association.	In	total,	
this	 research	 underscores	 the	 intricate	 influence	 that	 glucocorticoids	 can	 have	 on	
the	development	of	AUDs.	
In	 the	 present	 study,	 the	 influence	 of	 CORT	was	 evident	 not	 only	 on	 EtOH	
consumption,	but	also	on	EWD,	as	hormone	levels	were	found	to	be	at	T2	in	EtOH	
exposed	animals	but	not	in	water	treated	controls	(fig.	2.6a).	Finding	elevated	CORT	
in	 EtOH	 exposed	 animals	 during	withdrawal	 is	 consistent	 with	 a	 breadth	 of	 data	
regarding	HPA‐axis	dysregulation	that	occurs	in	the	human	population	during	EWD.	
Elevations	in	cortisol	have	been	reported	during	the	early	withdrawal	phase	(Esel	et	
al.,	2001),	which	is	followed	by	a	decline	in	hormone	levels	as	abstinence	progresses	
(Adinoff	et	al.,	1998;	von	Bardeleben	&	Holsbeer.,	1989).	In	some	alcohol‐dependent	
individuals,	 dysregulation	 of	 HPA‐axis	 activity	 is	 extreme,	 mirroring	 that	 seen	 in	
patients	with	Cushing’s	Syndrome	(Besemer	et	al.,	2011).	Supporting	data	have	been	
gathered	regarding	the	stress	response	using	long‐term	models	of	EtOH	exposure	in	
rodents.	 During	 the	 initial	 phase	 of	 EWD	 and	 following	 chronic	 EtOH	 treatment,	
elevations	 in	 plasma	 CORT	 (Alele	 &	 Devaud,	 2007;	 Rasmussen	 et	 al.,	 2000)	 and	
reductions	in	GR	mRNA	(Vendruscolo	et	al.,	2012)	were	observed,	while	increases	in	
GR	mRNA	were	observed	during	protracted	EWD	(Vendruscolo	et	al.,	2012).	These	
elevations	can	have	deleterious	results,	as	demonstrated	by	in	vivo	studies	in	which	
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exposure	to	CORT	was	shown	to	promote	neuronal	injury	within	the	hippocampus	
following	 EtOH	 exposure	 (Mulholland	 et	 al.,	 2005),	 the	 effects	 of	 which	 were	
glutamate	 receptor‐dependent	 (Butler	 et	 al.,	 in	 press;	 Mulholland	 et	 al.,	 2006).	
Additionally,	 neurochemical	 adaptations	 that	 occur	 during	 the	 withdrawal	 phase	
appear	 to	 be	 integral	 to	 the	 progression	 of	 dependence.	 This	 is	 demonstrated	 as	
escalation	of	drinking	and	worsening	of	withdrawal	symptoms	that	have	been	seen	
in	 animals	 exposed	 intermittently	 to	EtOH	 (allowing	 for	EWD	periods),	 but	not	 in	
those	exposed	to	the	continuous	treatment	(O’Dell,	2004).	Further,	there	is	evidence	
that	 these	 alterations	 are	GR‐dependent,	 as	 blocking	 the	 receptor	 is	 efficacious	 at	
reducing	 the	 escalation	 to	 drinking	 and	 the	manifestation	 of	withdrawal	 behavior		
(Cippitelli,	et	al,	2012;	Sharrett‐Field	et	al.,	2013;	Simms	et	al,	2012;	Vendruscolo	et	
al,	2012).		
At	 issue	with	 the	 interpretation	 that	 EtOH	 exposure	was	 found	 to	mediate	
elevations	in	CORT	during	withdrawal	(fig	2.6d),	is	the	lack	of	association	between	
hormone	elevations	and	EtOH	consumption	(presented	in	fig	2.10).	One	possibility	
for	 this	 occurrence	 is	 that	 EtOH	 consumption	 of	 any	 level	 sufficient	 in	 elevating	
CORT	during	protracted	withdrawal.	However,	 the	 results	may	 also	 arise	 from	an	
extraneous	 variable.	 Just	 prior	 to	 sacrifice,	 animals	 were	 placed	 in	 a	 restraining	
device	(DecapiCone,	Braintree	Scientific,	USA)	to	aid	in	decapitation.	This	restraint	
could	have	provided	a	stressor,	resulting	in	a	rise	in	CORT	levels.	In	support	of	this,	
hormone	 levels	 measured	 following	 1hr	 of	 EtOH	 exposure	 were	 significantly	
associated	 with	 those	 measured	 at	 T2,	 prior	 to	 decapitation	 (fig.	 2.6d).	 This	
association	 may	 have	 occurred	 because	 animals	 were	 stressed	 under	 both	
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conditions,	at	1hr	from	the	presentation	of	EtOH,	and	at	the	final	time	point,	due	to	
restraint	stress.	Additionally,	CORT	elevation	was	evident	in	water	control	animals	
prior	to	decapitation,	although	the	effect	was	not	significant	(fig	2.6a).	Therefore,	it	
is	possible	 that	 rise	 in	CORT	 levels	observed	 in	Figure	2.6a.	 is	mediated	by	stress,	
independent	of	EtOH	exposure.		
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Figure	2.10.	Plasma	CORT	levels	following	6	days	of	EWD	(T2)	was	not	associated	
with	EtOH	exposure.	 
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Finally,	it	is	interesting	to	note	that,	although	EtOH	is	known	to	activate	the	
HPA‐axis,	 thereby	 increasing	 CORT	 levels,	 no	 elevation	 is	 evident	 in	 animals	
following	1hr	of	access	 to	20%	EtOH	(fig	2.6a).	This	 is	 likely	because	only	modest	
EtOH	consumption	occurred	within	the	first	hour	of	access	(fig	2.5).	As	mentioned	
previously,	 a	more	 accurate	 representation	 of	 BEC	 could	 be	 assessed	 at	 the	 1200	
time	 point,	 when	 drinking	 is	 more	 robust	 (fig	 5).	 Additionally,	 although	 drinking	
levels	 following	 1hr	 of	 access	 were	 insufficient	 to	 detect	 an	 overall	 change	 from	
baseline	CORT	values	(fig	2.6a),	a	significant	correlation	was	found	between	CORT	
and	BEC	 (fig	 2.6c).	 This	 demonstrates	 that,	 in	 animals	 consuming	higher	 levels	 of	
EtOH	 during	 the	 first	 hour,	 consumption	 was	 sufficient	 to	 produce	 elevations	 in	
CORT.		
In	 sum,	 the	 CORT	 data	 suggested	 that	 basal	 CORT	 levels	 could	 provide	 a	
valuable	 biomarker	 for	 EtOH	 preference.	 Further,	 outbred	 animals	 consume	
sufficient	 levels	 of	 EtOH	 during	 intermittent	 exposure	 to	 elevate	 CORT	 levels,	
though	 further	 investigations	would	be	needed	to	determine	 if	elevations	 in	CORT	
occur	during	protracted	EWD.		
	
Acoustic	Startle	Reflex	
	 Testing	 conducted	 using	 ASR	was	 sensitive	 to	 the	 effects	 of	 EWD	 in	 these	
studies,	 as	EtOH	exposed	animals	 showed	significantly	elevated	 responding	 to	 the	
first	presentation	of	a	120dB	level	pulse	during	both	acute	and	protracted	EWD	(fig	
2.7).	 Importantly,	 EWD	 is	 a	 defining	 characteristic	 of	 dependence	 (American	
Psychiatric	Association,	1994).		The	manifestation	of	EWD	in	rodents	can	present	as	
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local	or	whole‐body	tremor,	rigidity	(tail	and	body),	enhanced	seizure	susceptibility	
(handling‐	 and	 auditory‐induced)	 or	 less	 overtly	 in	 anxiety‐like	 behaviors	 (i.e.,	
decreased	 exploratory	 behavior)	 (Helig	 et	 al.,	 2010).	 Similarly,	 humans	 can	
experience	 seizures	 and	 increased	 anxiety	 during	 EWD.	 Alterations	 in	 ASR	 have	
been	 used	 to	 assess	 anxiety	 disorders	 in	 humans	 (Grillon	 et	 al.,	 1997),	 as	well	 as	
depression	 (Grillon	 et	 al.,	 1997;	 Mneime	 et	 al.,	 2008),	 childhood	 abuse,	 post‐
traumatic	 stress	 disorder	 (PTSD)	 (Grillon	 et	 al.,	 1996;	 reviewed	 by	 Braff	 et	 al.,	
2001),	 or	 substance	 abuse	 (Grillon	 et	 al.,	 2008),	 which	 all	 have	 in	 common	 an	
interaction	 with	 the	 stress	 response.	 In	 fact,	 injections	 of	 corticotropin‐releasing	
hormone	(CRH)	are	able	to	enhance	the	startle	response,	an	affect	that	is	mediated	
by	the	efferent	projections	of	the	ventral	hippocampus	onto	the	bed	nucleus	of	the	
stria	terminalis	(BNST),	as	lesions	to	either	resulted	in	decreased	CRH	enhancement	
of	 ASR	 (Lee	&	 Tsai,	 1989;	 Lee	&	Davis,	 1997).	 Additionally,	 administration	 of	 the	
centrally	 acting	 hypertension	drug	moxondine	was	 able	 to	 reduce	EWD‐enhanced	
ASR	 (Vandergriff	 et	 al.,	 2000).	 This	 drug	 is	 an	 agonist	 at	 the	 imidazoline(I)(1)	
receptor,	which	are	centrally	distributed	and	are	expressed	in	the	medulla,	ventral	
tegmental	area,	and	peripherally	 in	 the	adrenal	medulla.	 Interestingly,	 intensity	of	
ASR	has	been	associated	with	the	number	of	withdrawal	episodes	an	individual	has	
experienced,	 in	which	a	threshold	of	2	or	more	detoxifications	has	been	suggested	
(Krystal,	1997).	These	findings	suggest	that	ASR	is	sensitive	to	the	kindling	effects	
associated	with	EWD,	 indicative	of	 a	hypersensitivity	within	 the	CNS	 (Ballenger	&	
Post,	1978;	recently	reviewed	by	Breese	et	al,	2011).	Because	the	IA	model	of	EtOH	
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exposure	allows	 for	 repeated	periods	of	withdrawal	 from	EtOH,	 it	 is	possible	 that	
elevations	in	ASR	are	due	to	the	effects	of	kindling.		
Although	 no	 treatment	 effect	 was	 found	 regarding	 measures	 of	 startle	
plasticity	(HAB	and	PPI),	the	data	did	yield	important	information	that	may	impact	
the	overall	interpretation	of	this	study.	In	analyzing	both	HAB	and	PPI	data,	a	main	
effect	 of	 day	 was	 observed,	 such	 that	 baseline	 values	 were	 significantly	 different	
than	those	of	either	later	time	points	(figs	2.8	&	2.9a).	In	fact,	very	little	habitation	or	
inhibition	 was	 observed	 during	 baseline	 measurements.	 This	 pattern	 of	 reduced	
responding	 is	 known	 to	 occur	 in	 adolescent	 animals.	 Regarding	 PPI,	 younger	
animals	 are	 believed	 to	 lack	 the	 ability	 to	 filter	 out	 irrelevant	 stimuli,	 thereby	
reducing	effectiveness	of	the	prepulse	to	predict	the	subsequent	pulse	(Ellwanger	et	
al.,	 2003;	 van	 den	 Buuse,	 2003;	 and	 reviewed	 by	 Geyer	 et	 al.,	 2001).	 It	 has	 been	
suggested	 that	 this	 lack	 of	 inhibition	 results	 from	 an	 underdeveloped	 prefrontal	
cortex	 (Ellwanger	 et	 al.,	 2003;	 van	 den	 Buuse,	 2003).	 In	 the	 current	 study,	
presentation	 of	 the	 prepulse	 reduced	 baseline	 responding	 by	 ~40%,	 whereas	
reductions	 exceeding	 60%	were	 observed	 at	 later	 time	 points	 (fig	 2.9a).	 	 Similar	
results,	 published	 by	 Brunell	 &	 Spear	 (2006),	 showed	 significantly	 less	 PPI	 at	
baseline	 in	adolescent	Sprague‐Dawley	rats	 (post	natal	day	 (PND)	30‐31)	 (~30%)	
than	 in	 adults	 (PND	 69‐71)	 (~60%).	 The	 acceptable	 age	 range	 for	 reaching	
adulthood	in	rats	has	been	debated	in	the	literature,	but	based	upon	factors	such	as	
growth	spurt,	loss	of	NMDA	in	the	PFC,	and	exiting	of	the	nest	in	the	wild,	post‐natal	
day	 (PND)	 28‐43	 appears	 to	 be	 a	 conservative	 range	 for	 the	 end	 of	 adolescence	
(reviewed	by	Spear,	2000).	However,	signaling	changes	associated	with	maturation	
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can	occur	as	late	as	PND55	(250‐275g)	(Spear,	2000).	Animals	used	in	the	present	
studies	were	PND60,	with	an	average	weight	of	220g,	placing	them	on	the	edge	of	
these	parameters.	 If,	 in	 fact,	 these	animals	were	still	undergoing	development,	 the	
effects	demonstrated	here	may	be	exclusive	to	adolescent	EtOH	exposure.		
Suggestive	 of	 this	 interpretation,	 abstinent	 alcohol‐dependent	 males	 who	
began	drinking	during	adolescence	(mean	age	of	onset	=18)	had	elevated	ASR	(eye‐
blink)	as	compared	 to	abstinent	 individual	who	began	drinking	 later	 in	 life	 (mean	
age	of	onset=30)	(Schellekens	et	al,	2012).	While	these	results	may	indicate	possible	
genetic	 differences	 between	 these	 groups	 similar	 to	 those	 seen	 in	 relatives	 of	
alcoholics,	it	is	important	not	to	exclude	the	effect	of	EtOH	exposure	during	the	final	
stages	 of	 development.	 In	 fact,	 early	 onset	 drinking	 is	 a	 strong	 predictor	 of	 later	
alcohol	abuse	and	dependence,	with	probabilities	increasing	significantly	if	drinking	
begins	prior	 to	 age	19	 (DeWit	 et	 all,	 2000),	which	has	been	defined	as	 the	 end	of	
adolescence	by	the	World	Health	Organization.	Preclinical	research	supports	this,	as	
adolescent	but	not	adult	rodents,	experience	enhanced	voluntary	drinking	following	
the	presentation	of	minor	environmental	stressors	(e.g.,	isolated	housing)	(Doremus	
et	 al,	 2005).	 Indeed,	 there	 is	 accumulating	 evidence	 that	 adolescents	 experience	
fewer	 effects	 that	 are	 associated	 with	 the	 regulation	 of	 drinking	 (e.g.,	 sedation,	
anxiety	 upon	 withdrawal),	 while	 experiencing	 more	 of	 the	 neurodegenerative	
effects	 that	can	promote	addiction	(reviewed	by	Nixon	&	McClain,	2010).	A	recent	
study	 into	 mechanisms	 that	 may	 contribute	 to	 early	 onset	 drinking	 identified	
several	GR	polymorphisms	to	be	associated	with	alcohol	use	and	abuse	in	a	group	of	
14	year	old	adolescents	(Desrivieres	et	al,	2011).		
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Collectively,	the	ASR	data	collected	here	suggest	that	consumption	resulting	
from	IA	EtOH	exposure	is	sufficient	to	produce	dependence.	However,	it	remains	to	
be	 seen	 if	 these	 effects	 are	 dependent	 upon	 the	 age	 of	 the	 animal	 during	 initial	
exposure.		
	
Protein	Analysis	
	 Literature	regarding	upregulation	of	NR2B	receptor	subunits	following	EtOH	
exposure	 within	 the	 hippocampus	 and	 PFC	 are	 not	 without	 precedent,	 although	
studies	 have	 produced	 mixed	 results.	 For	 example,	 chronic	 EtOH	 exposure	 was	
found	 to	 elevate	 levels	 of	NR2B	 in	 the	 forebrain	 (Narita	 et	 al,	 2000)	 and	 cerebral	
cortex	(Henniger	et	al,	2003;	Kumari	&	Ticku,	1998)	(but	see	also	Narita	et	al.,	2000)	
and	hippocampus	(Butler	et	al,	 in	press).	These	elevations	have	been	implicated	in	
CNS	hyperexcitiblity	 that	 results	upon	EWD	 (reviewed	by	Kumari	&	Ticku,	2000).	
Lack	 of	 evidence	 in	 the	 present	 study	 should	 not	 be	 interpreted	 as	 conclusive,	 as	
there	 is	 evidence	 of	 region‐specificity	 regarding	 EtOH‐induced	 alterations	 of	 the	
NR2B	and	the	current	studies	investigated	alteration	in	the	entire	are	of	the	PFC	and	
hippocampus.		
As	 previously	 discussed,	 EtOH	 is	 able	 to	 affect	 the	 expression	 of	 GRs	 in	
several	 different	 brain	 regions	 during	 EtOH	 intake	 and	withdrawal.	 (Eskay	 et	 al.,	
1995;	Roy	et	al.,	2002;	Vendruscolo	et	al.,	2012;	Vendruscolo	et	al.,	2012;	Roy	et	al.,	
2002).	In	the	present	study,	no	significant	alterations	in	GR	were	found	following	6	
days	of	EWD.	However,	a	trend	toward	upregulation	was.	This	finding	is	consistent	
with	 results	 of	 a	 recent	 publication	 in	 which	 EtOH	 exposure	 via	 vapor	 chamber	
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resulted	 in	decreases	 in	GR	mRNA	(hippocampus,	PFC,	nucleus	accumbens,	BNST)	
24hrs	 following	 the	 withdrawal	 of	 EtOH	 and	 elevations	 in	 GR	 mRNA	 (nucleus	
accumbens,	 BNST,	 amygdala)	 3	weeks	 later	 evident	 (Vendruscolo	 et	 al,	 2013).	An	
upregulation	of	GR	during	protracted	withdrawal	may	have	implications	regarding	
stress‐induced	 relapse,	 as	 abstinent	 individuals	 may	 experience	 increased	
sensitivity	HPA‐axis	activation.	In	fact,	preclinical	studies	have	shown	an	escalation	
in	drinking	following	protracted	withdrawal	(O’Dell	et	al,	2004),	which	is	escalated	
by	 stress	 (reviewed	 by	 Breese	 et	 al,	 2010),	 but	 which	 is	 also	 blocked	 by	 GR	
antagonists	(Simms	et	al,	2012).	Together,	these	data	suggest	the	GR	is	as	a	possible	
therapeutic	target	in	the	treatment	of	alcohol	dependence	and	relapse.		
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Chapter	Three	
EFFECTS	OF	THE	ADMINISTRATION	OF	THE	SELECTIVE	GLUCOCORTICOID	
RECEPTOR	ANTAGONIST	ORG‐34517	ON	VOLUNTARY	ETHANOL	CONSUMPTION	
AND	SUBSEQUENT	ETOH	WITHDRAWAL	
(Study	2;	Sharrett‐Field,	et	al.)	
Introduction		
Alcoholism	is	a	devastating	disorder,	by	some	accounts	affecting	up	to	15%	
of	 the	 American	 population.	 Individuals	 often	 repeatedly	 shift	 from	 periods	 of	
dependence,	 withdrawal,	 abstinence,	 relapse,	 and	 back	 to	 dependence.	 In	 fact,	
relapse	 rates	 range	 from	 20‐80%,	 underscoring	 the	 cyclic	 nature	 of	 the	 disease.			
Repeated	 alcohol	 withdrawal	 is	 problematic	 in	 that	 subsequent	 withdrawal	
episodes	 have	 been	 associated	 with	 a	 worsening	 of	 symptoms	 (withdrawal	
sensitization),	 which	 can	 culminate	 in	 seizure	 activity	 and	 persistent	
neuroadaptations.	 	 Currently,	 individuals	 presenting	 with	 alcohol	 withdrawal	 are	
treated	 with	 barbiturates	 and	 other	 CNS	 depressants	 or	 anti‐consultants.	 While	
these	 drugs	 are	 successful	 in	 reducing	 seizure	 activity	 and	 increasing	 short‐term	
abstinence,	 they	 have	 not	 been	 shown	 to	 reduce	 withdrawal	 sensitization	 or	
promote	 long‐term	abstinence.	 	Medications	such	as	disulfiram,	acamprosate,	 and,	
naltrexone	 have	 demonstrated	 some,	 yet	 limited,	 success	 in	 achieving	 long	 term	
abstinence.	 However,	 they	 have	 not	 shown	 efficacy	 in	 reducing	 withdrawal	
sensitization.	 Importantly,	 withdrawal	 sensitization	 has	 been	 associated	 with	
changes	 in	 the	 rewarding	 characteristics	 of	 alcohol,	 increasing	 both	 negative	 (i.e.,	
anxiety)	and	positive	(i.e.,	increased	consumption	following	relapse)	reinforcement;	
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these	 factors	 are	 believed	 to	 lead	 to	 increased	 rates	 of	 relapse.	 Therefore,	
developing	treatments	that	are	efficacious	at	reducing	consumption	and	withdrawal	
could	offer	additive	protection	against	relapse	to	drinking.	
Stress	 is	 a	 known	 contributor	 to	 the	 development	 and	 escalation	 of	
alcoholism	and	also	plays	a	main	role	 in	relapse	drinking.	Major	 life	stressors	 (ie.,	
loss	 of	 a	 job,	 moving,	 chronic	 health	 related	 issues)	 are	 associated	 with	 lifetime	
alcohol	consumption	and	risk	of	developing	an	AUD	(Veenstra	et	al,	2006).	However,	
the	question	as	to	why	these	external	risk	factors	induce	some	individuals	to	abuse	
alcohol,	while	others	seek	more	adaptive	means	of	coping,	remains	an	unanswered	
question.	 Accumulating	 evidence	 suggests	 that	 how	 an	 individual	 reacts	 to	 stress	
can	be	a	contributing	factor	to	the	development	of	an	alcohol	abuse	disorder	(AUD),	
which	 in	 turn	 is	mediated	 by	 one’s	 genetic	 profile.	 Twin	 studies	 suggest	 that	 the	
basal	 state	 and	 reactivity	 of	 the	 body’s	 main	 stress	 system,	 the	 HPA‐axis,	 is	 a	
heritable	 trait	 (Bartels	 et	 al,	 2003).	 Additionally,	 children	 of	 individuals	 who	 are	
alcohol	 dependent	 have	 both	 an	 altered	 stress	 response	 and	 a	 propensity	 for	
developing	 alcoholism,	 suggesting	 a	 genetic	 link	 for	 both	 traits	 (Uhart	 &	 Wand,	
2008;	Zimmerman	et	al,	2007).	Preclinical	data	support	the	link	between	stress	and	
the	 development	 of	 AUD,	 as	 altering	 levels	 of	 the	 primary	 stress	 hormone	
corticosterone	 (CORT)	 in	 rodents	 can	 elevate	 or	 decrease	 EtOH	 consumption	
(Fahlke	et	al.,	1994a,	b;	Falke	&	Hansen,	1995;	Hansen	et	al.,	1995;	de	Witte	et	al,	
1996;	Hansen	et	al.,	1995,	Fahlke	et	al,	1994).	Further	targeting	the	glucocorticoid	
receptor	 (GR),	 a	 primary	 receptor	 of	 CORT,	 with	 the	 antagonist	mifepristone	 can	
reduce	 voluntary	 consumption	 (Koenig	 &	 Olive,	 2004;	 Vendruscolo	 et	 al,	 2012),	
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stress‐induced	 EtOH	 seeking	 (Simms	 et	 al.,	 2011),	 behavioral	 signs	 of	 ethanol	
withdrawal	(EWD)	(Sharrett‐Field	et	al.,	2013)	and	cognitive	deficits	resulting	from	
EWD	(Jaquot	et	al.,	2008).	While	the	traditional	antagonist	mifepristone	is	effective	
in	 treating	these	correlates	of	alcohol	abuse	 in	preclinical	models,	 implications	 for	
its	 clinical	 use	 are	 less	 optimistic,	 as	 it	 is	 a	 potent	 progesterone	 receptor	 (PR)	
antagonist.	Activity	at	the	PR	is	needed	to	sustain	pregnancy;	therefore	prescription	
of	 mifepristone	 would	 likely	 be	 limited	 to	 the	 male	 population.	 A	 derivative	 of	
mifepristone,	 11,	 21	 Bisphenyl‐19norpreganane	 (ORG‐34517)	 displays	 a	 high	
affinity	for	GR	binding	with	negligible	binding	to	the	PR	(affinity	ration	for	GR/PR	of	
488)	(Gebhard	et	al,	1997),	suggesting	it	is	a	suitable	replacement	for	mifepristone.		
The	 following	study	was	conducted	 to	determine	 the	effects	administration	
of	 the	 selective	 GR	 antagonist	 ORG‐34517	would	 have	 on	 voluntary	 consumption	
levels	 and	 subsequent	 EWD.	 An	 intermittent	 access	model	 of	 EtOH	 exposure	was	
used	and	drug	was	delivered	via	inclusion	in	the	consumer	grade	product,	Nutella®.	
It	 was	 hypothesized	 that	 ORG‐34517	 would	 decrease	 voluntary	 consumption	 of	
20%	EtOH.	 Attenuation	 of	 EtOH‐dependent	 changes	 in	ASR	 during	 EWD	was	 also	
anticipated.	 However,	 elevations	 in	 CORT	 were	 anticipated	 in	 the	 ORG‐34517	
treated	animals,	as	blocking	the	GR	also	blocks	the	natural	feedback	mechanism	for	
the	 stress	 response.	 Assessment	 of	 protein	 levels	 was	 conducted	 in	 the	
hippocampus	 and	 the	 medial	 pre‐frontal	 region	 of	 the	 frontal	 cortex	 (mPFC)	 to	
assess	the	state	of	GR	and	NR2B	protein	expression,	as	well	as	the	phosphorylation	
state	 of	 the	 NR2B	 receptor.	 EtOH‐associated	 elevations	 in	 GR	 and	 pNR2B	 were	
expected.		 	
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Materials	and	Methods	
The	 following	section	closely	 follows	methods	detailed	 in	Chapter	2.	For	 the	reader’s	
convenience,	changes	and	additions	have	been	underlined.	
	
Subjects		
Male,	 Long‐Evans	 rats	 (60	 days	 old;	 Harlan	 Laboratories,	 Indianapolis,	 IN)	
were	single	housed	and	exposed	to	reversed	dark/light	cycle	(lights	off	at	0900hrs).	
During	a	one	week	acclimation	period,	animals	were	handled	 for	20min/day	for	3	
days.	Animal	and	 food	weights	were	 taken	weekly	between	0800	and	0900hrs	on	
Monday.	 Animals	 had	 ad	 libitum	 access	 to	 food	 and	 water	 throughout	 the	
experimental	procedure.	
	
Intermittent	Access	to	Ethanol		
Animals	 were	 given	 24hrs	 of	 concurrent	 access	 to	 1	 standard	 bottle	
containing	a	20%	(v/v)	EtOH/water	solution	and	one	standard	bottle	containing	tap	
water.	After	24hrs,	EtOH	bottles	were	 removed	and	all	 animals	 received	2	bottles	
containing	tap	water	(for	Experimental	Timeline,	see	Table	3.1).		Placement	of	EtOH	
and	water	bottles	were	alternated	 to	avoid	side	preference.	This	pattern	of	access	
(24hrs	with	EtOH	followed	by	24hrs	without	EtOH)	continued	for	55	days	(27	days	
of	 EtOH	 exposure	 on	 M‐W‐F).	 Two	 empty	 cages	 containing	 no	 animals	 received	
identical	 treatment	 regarding	 bottle	 changes	 and	 served	 to	 account	 for	 bottle	
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leakage	 (leak	 controls).	 A	 separate	 group	 of	 animals	 (water	 controls)	 received	
identical	treatment	except	neither	bottle	contained	EtOH.		
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Table	3.1	Experimental	Timeline	
	
	 M	 T W TH F	 Sa Su
WK1	 T0 
Baseline ASR 
 Blood Draw 
EtOH/Water 
 
Water/Water 
 
EtOH/Water 
 
Water/Water 
	
	
WK2	 EtOH/Water Water/Water EtOH/Water Water/Water EtOH/Water Water/Water 	
WK3	 EtOH/Water Water/Water EtOH/Water Water/Water EtOH/Water Water/Water 	
WK4	 EtOH/Water Water/Water EtOH/Water Water/Water EtOH/Water Water/Water 	
WK5	 EtOH/Water Water/Water Blood Draw 
EtOH/Water 
Water/Water EtOH/Water Water/Water 	
WK6	 EtOH/Water Water/Water EtOH/Water Water/Water EtOH/Water Water/Water 	
WK7	 ORG or Nutella 
EtOH/Water 
Water/Water ORG or Nutella 
EtOH/Water 
Water/Water ORG or Nutella 
EtOH/Water 
Water/Water 	
WK8	 ORG or Nutella 
EtOH/Water 
Water/Water ORG or Nutella 
EtOH/Water 
Water/Water ORG or Nutella 
EtOH/Water 
Water/Water 	
	
WK9	 ORG or Nutella 
EtOH/Water 
Water/Water ORG or Nutella 
EtOH/Water 
Water/Water ORG or Nutella 
EtOH/Water 
Water/Water 	
	
	
WK	
10	
ORG or Nutella 
EtOH/Water 
Water/Water Water/Water 
T1 ASR 
Water/Water Water/Water Water/Water 	
WK	
11	
T2 ASR 
Sacrifice- 
Trunk Blood 
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Measures	of	Ethanol	Consumption	
	 EtOH	 consumption	 was	 measured	 in	 two	 manners.	 First,	 bottles	 given	 to	
animals	(water	and	EtOH)	were	weighed	prior	to	presentation	and	again	following	
24hrs	 of	 access.	 This	 value,	 less	 the	 weight	 change	 detected	 in	 the	 leak	 control	
bottles,	was	 expressed	 as	ml/kg	 of	 fluid	 intake.	 Twenty	 percent	 of	 this	 value	was	
multiplied	 by	 the	 specific	 gravity	 of	 200	 proof	 EtOH	 (0.794cm)	 to	 determine	 the	
EtOH	dose	(g/kg)	each	animal	received.	Additionally,	blood	EtOH	concentration	was	
measured	 following	 1Hr	 of	 access,	 as	 described	 below.	 No	 video	 recordings	were	
conducted	in	these	experiments.		
	
Drug	Treatment	
These	studies	used	the	selective	GR	antagonist	ORG‐34517	to	investigate	the	
effect	of	GR	antagonism	on	EtOH	consumption	and	EWD.	ORG‐34517	is	chemically	
similar	 to	RU‐486,	which	has	been	shown	to	reduce	voluntary	EtOH	consumption,	
EtOH	reinstatement,	EWD	and	cognitive	deficits	resulting	from	EtOH	exposure	and	
subsequent	withdrawal,	but	does	have	some	beneficial	properties	over	RU‐486.	For	
example,	while	RU‐486	shows	high	affinity	 for	 the	GR,	 it	does	show	activity	at	 the		
progesterone	receptor	 (PR)	as	well.	 	Blocking	 this	 receptor	produces	spontaneous	
termination	of	pregnancy,	making	administration	of	the	drug	unsuitable	for	women	
who	are	or	may	become	pregnant,	thus	limiting	the	drug’s	clinical	use.	ORG‐34517	is	
selective	 for	 the	 GR	 and	 shows	 little	 to	 no	 affinity	 for	 the	 PR.	 	 Additionally,	 the	
mechanism	of	 action	 for	 each	drug	differs	 slightly.	 The	GR	 is	 a	 cytosolic	 receptor,	
which	is	inactively	bound	by	chaperone	proteins	within	the	cytosol.	Binding	of	CORT	
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to	 the	 receptor/chaperone	 complex	 initiates	 a	 conformation	 change	 and	 the	
chaperone	 dissociates.	 The	 CORT/GR	 complex	 is	 then	 able	 to	 translocate	 to	 the	
nucleus	where	the	complex	can	begin	the	process	of	protein	synthesis.	Both	RU‐486	
and	ORG‐34517	compete	with	CORT	for	the	GR	binding	in	the	cytosol.	However,	co‐
exposure	of	RU‐486	and	CORT	results	in	no	reduction	in	translocation	of	the	GR	to	
the	 nucleus	 whereas	 co‐exposure	 with	 ORG‐34517	 and	 CORT	 results	 in	 a	 75%	
reduction	 in	 translocation	 (Peeters	 et	 al.,	 2008).	 Due	 to	 the	 chemical	 and	
mechanistic	similarities	between	RU‐486	and	ORG‐34517,	it	was	hypothesized	that	
the	latter	would	be	effective	at	reducing	consumption	in	the	present	model.	Due	to	
its	 selectivity	 for	 the	 GR,	 ORG‐34517	 would	 be	 available	 to	 a	 larger	 clinical	
population,	as	compared	to	RU‐486.						
	 Following	 week	 5,	 EtOH	 exposed	 animals	 were	 matched	 for	 consumption	
levels	 (g/kg)	 and	 distributed	 across	 drug	 treatment,	 such	 that	 both	 high	 and	 low	
consumers	were	equally	 represented,	 and	water	 control	 animals	 received	 random	
assignment	(average	consumption	(g/kg):	ORG‐34517=4.1,	±1.3,	placebo=3.4,	±3.4.	
This	 time	 point	 was	 selected	 based	 upon	 previous	 data,	 which	 suggest	 that	
voluntary	consumption	has	stabilized	at	this	point.	The	selective	GR	antagonist	ORG‐
34517	or	placebo	(compliments	of	Pop	Test,	Cliffside	Park,	NJ)	was	delivered	M‐W‐
F,	1hr	prior	to	the	presentation	of	EtOH	bottles.	Capsules	containing	drug	(150mg)	
or	placebo	were	opened	and	added	to	Nutella®	(150mg/2g)	and	mixture	was	placed	
in	a	Ziploc®	bag.	Through	a	cut	in	the	corner	of	the	bag,	0.53mg/kg	was	measured	
out,	resulting	in	a	40mg/kg	dose	at	each	time	point.	Nutella®	mixture	was	delivered	
by	placing	 the	 entire	dose	on	 the	 inside	wall	 of	 each	 animal’s	 cage	 (drug	delivery	
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visually	 detailed	 in	 figures	 3.1a,	 b,	 c).	 At	 each	 presentation,	most	 animals	 readily	
(within	5min)	consumed	the	entire	dose	of	mixture,	and	all	animals	consumed	the	
entire	amount	of	mixture	in	the	30min	prior	to	the	delivery	of	EtOH.	This	method	of	
drug	 delivery	 was	 selected,	 as	 it	 made	 use	 of	 the	 capsules	 as	 they	 had	 been	
formulated	 (i.e.,	 for	 oral	 ingestion)	 and	 had	 the	 added	 benefit	 of	 minimizing	 the	
stress	incurred	by	the	experimental	animals.		
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a. b. c. 
Figure	3.1a. Figure	3.1b. Figure	3.1c. 
Figure	3.1a‐c.	Delivery	of	ORG‐34517	or	placebo	in	vehicle	(Nutella®).	Capsules	containing	drug	
(150mg)	 or	 placebo	 were	 opened	 and	 added	 to	 Nutella®	(150mg/2g),	 mixed	 and	 placed	 in	 a	
Ziploc®	bag	(a).	Through	a	cut	in	the	corner	of	the	bag,	0.53mg/kg	was	measured	out,	resulting	
in	a	40mg/kg	dose	at	each	time	point	(b.).	Nutella®	mixture	was	delivered	by	placing	the	entire	
dose	on	the	inside	wall	of	each	animal’s	cage	(c.). 
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Blood	Ethanol	and	Corticosterone	Concentration		
Tail	blood	was	collected	(approximately	140	µl/animal/time	point)	prior	to	
EtOH	exposure	and	again	1hr	following	the	introduction	of	EtOH	during	week	6.	Six	
days	following	the	removal	of	EtOH,	animals	were	euthanized	via	rapid	decapitation	
and	 trunk	blood	was	collected.	Upon	collection,	blood	samples	were	placed	on	 ice	
and	 centrifuged	 (5	 min	 at	 15,000	 g/min);	 blood	 plasma	 was	 collected	 and	
immediately	stored	at	‐80°C.		
Blood	EtOH	levels	(BEL)	were	determined	using	the	Analox	AM1	instrument	
(Analox	Instruments,	Lunenburg,	MA),	which	measures	blood	EtOH	concentrations	
indirectly	 through	 measurement	 of	 molecular	 oxygen	 levels.	 In	 the	 presence	 of	
molecular	 oxygen,	 EtOH	 is	 oxidized	 by	 the	 enzyme	 alcohol	 oxidase	 to	 form	
acetaldehyde	 and	 hydrogen	 peroxide.	 Under	 the	 conditions	 of	 the	 assay,	 oxygen	
consumption	is	directly	proportional	to	EtOH	concentration	in	the	plasma	sample.	
Blood	 CORT	 levels	 (BCLs)	 were	 determined	 using	 a	 competitive	 EIA	
Corticosterone	kit	(IDS	Limited,	Fountain	Hills,	AZ).	 	Briefly,	100	µl	of	each	diluted	
sample	(1:20),	calibrator,	and	control	and	100µl	of	enzyme	(corticosterone	labeled	
with	 horseradish	peroxidase)	were	 added	 to	 an	 antibody	 coated	plate	 (polyclonal	
rabbit	anti‐corticosterone)	in	duplicate	and	incubated	at	4°C	for	24	hrs.	 	Following	
incubation,	 the	 plate	 was	 thrice	 washed	 and	 200	 µl	 of	 substrate	
(tetramethylbenzidine	 and	 hydrogen	 peroxide)	 was	 added.	 	 After	 30	 min,	 stop	
solution	(0.5M	hydrochloric	acid)	was	added	and	 the	microplate	was	read	using	a	
Beckman	 Coulter	 DTX	 880	 Mulitmodal	 Detector	 (Lagerhausstrasse,	 Austria)	 with	
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Beckman	 Coulter	 Multimode	 Detection	 Software	 (v.20.0.12).	 	 Mean	 absorbance	
values	for	samples,	controls,	and	calibrators	were	measured	at	450nm	producing	a	
mean	 value;	 this	 value	 was	 used	 to	 calculate	 percent	 binding	 (B/B0%=[(mean	
absorbance)/(mean	 absorbance	 for	 “0”	 calibrator)]×100).	 	 Mean	 concentration	 of	
CORT	 for	 each	 sample	 (ng/ml)	was	 determined	 based	 upon	 the	 calibration	 curve	
defined	by	known	samples	that	were	run	with	the	experimental	samples.		
	 	 	 	
Behavioral	Measures	
Acoustic	Startle	Reactivity	was	measured	in	a	commercially	available	startle	
system	(S‐R	Lab,	San	Diego,	CA,	USA).	Chambers	(35x33x38.5	cm,	 length	x	width	x	
height)	contained	an	overhead	 light	 (3	 lux)	and	a	Plexiglas	holding	tube	(8.9cm	in	
diameter	x	20.3cm	in	length),	in	which	animals	were	placed	for	testing.	The	holding	
tube	was	designed	to	reduce	but	not	eliminate	voluntary	movement	of	the	animal,	
thereby	reducing	stress.	A	piezoelectric	accelerometer	within	each	tube	transduced	
large	movement	by	the	animal	and	was	attached	to	a	PC,	on	which	responses	were	
recorded	 using	 S‐R	 Lab	 software	 (v5.0).	 A	 speaker	 located	 in	 the	 ceiling	 of	 the	
chamber	delivered	acoustic	startle	stimuli	as	well	as	75dB	white	noise	background.	
At	 the	 beginning	 of	 each	 trial	 (defined	 below),	 data	were	 recorded	 over	 a	 100ms	
window	and	were	 sampled	 at	 1ms	 intervals.	 Data	were	 recorded	 in	 two	different	
chambers.	 Both	 input	 (dB)	 and	 output	 (amplitude	 of	 response)	 were	 calibrated	
prior	to	each	testing	session	using	San	Diego	Instruments	calibration	devices.		
		Data	 consisted	 of	 two	 measures,	 startle	 reactivity	 (first	 startle	 response	
(FSR))	 and	 startle	 plasticity	 (habituation	 of	 the	 startle	 response	 and	 prepulse	
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inhibition).	 ASR	 data	was	 collected	 prior	 to	 EtOH	 exposure	 (T0)	 and	 again	 26hrs	
(T1)	and	6	days	(T2)	after	EtOH	exposed	animals	received	the	final	EtOH	exposure.	
These	 time	 points	 were	 chosen	 to	 reflect	 both	 acute	 and	 protracted	 EWD	 in	 the	
EtOH	exposed	animals.	During	IA	access,	EtOH	exposed	animals	become	accustomed	
to	 experiencing	 24hrs	 between	 EtOH	 exposures.	 Therefore,	 at	 26hrs	 (T1),	 it	 was	
reasoned	that	animals	would	have	expected,	but	not	received	EtOH,	a	situation	that	
would	elevate	anxiety	in	dependent	animals.		
Prior	to	all	ASR	testing	a	5	min	acclimation	period	consisting	of	background	
noise	 (75dB	white	noise)	was	presented	and	remained	on	 throughout	 testing.	For	
measures	 of	 FSR	 and	 habituation,	 animals	 were	 presented	 with	 6	 120dB	 stimuli	
(Sandbak	et	al,	2000).	The	FSR	is	equivalent	to	the	amplitude	of	the	startle	response	
to	 the	 initial	 presentation	 of	 a	 120dB	 stimulus	 tone.	 Habituation	 score	 was	
calculated	by	subtracting	the	average	amplitude	of	 the	 last	 three	startle	responses	
from	 the	 average	 of	 the	 initial	 three	 responses.	 Prepulse	 inhibition	 (PPI)	 was	
assessed	over	8	blocks	consisting	of	a	random	presentation	of	the	following	5	trials:																								
			 	 (i)			Pulse	stimulus	(110	dB	for	40ms)		
			 	 (ii)		Prepulse	A(4dB	for	20ms)	+	pulse	stimulus	
			 	 (iii)	Prepulse	B(8dB	for	20ms)	+	pulse	stimulus	
			 	 (iv)	Prepulse	C(16dB	for	20ms)	+	pulse	stimulus	
			 	 (v)	No	stimulus	(background	noise	was	applied)	
	
PPI	 was	 defined	 as	 a	 decrease	 in	 the	 amplitude	 of	 the	 startle	 response	 in	 the	
presence	of	the	prepulse	stimuli	and	expressed	as:	PPI	=	(100‐(mean	startle	reflex	
with	 the	 prepulse/mean	 startle	 reflex	 without	 prepulse))	 x	 100	 (Geyer,	 2001).	
Interval	between	the	presentation	of	 the	prepulse	and	pulse	was	100ms,	 intertrial	
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intervals	 were	 varied	 randomly	 in	 the	 range	 of	 10	 to	 30s.	 Total	 time	 in	 startle	
chamber	for	each	animal	was	approximately	25	minutes.		
	
Protein	Expression	
	 Following	 rapid	 decapitation,	 whole	 brains	 were	 removed.	 Olfactory	 bulbs	
were	 discarded	 and	 medial	 prefrontal	 cortex	 (mPFC)	 was	 isolated	 from	 each	
hemisphere;	 following	 sagittal	 section,	 hippocampi	 were	 bi‐laterally	 removed.	
Tissue	from	each	brain	region	was	placed	on	dry	ice	immediately	following	removal	
and	 stored	 at	 ‐80°C.	 Frozen	 tissue	 was	 placed	 in	 lysis	 buffer	 (Radio‐
Immunoprecipation	Assay	 (RIPA)	Buffer	 (1:100)	 (Thermo	 Scientific,	 Rockford	 IL),	
99.8M‐6	PMSF/EtOH	(Sigma‐Aldrich,	St.	Louis	MO)		in	PBS	(1:100),	HALT	Protease	&	
Phosphotase	 Inhibitor	 (1:10)	 (Thermo	 Scientific,	 Rockford	 IL)),	 coarsely	 ground	
using	 a	 pestle,	 and	 centrifuged	 at	 4°C	 for	 20min	 at	 12000rpm.	 Supernantant	was	
collected	and	assayed	using	the	Pierce®	BCS	Protein	Assay	Kit	(Fisher)	to	determine	
the	protein	concentration	of	each	sample.		
Immunoblotting	 was	 conducted	 in	 the	 Mini‐Protean®	 System	 using	 TGX	
Gradient	Precast	Gels	(4‐15%)	(Bio‐Rad,	USA).	Prepared	samples	(10uL	containing	
50ug	of	protein)	or	Bio‐Rad	Precision	Plus	Protein™	standards	(7uL)	were	vortexed	
and	 loaded	 into	 lanes.	 Samples	 were	 electrophoresed	 in	 1x	 Tris/glycine/sodium	
dodecyl	 sulfate	 buffer	 (Bio‐Rad,	 Hercules,	 CA,	 USA)	 at	 room	 temperature	 for	
approximately	 2.5	 hrs	 at	 80‐90V.	 Protein	 was	 transferred	 on	 the	 membrane	
(nitrocellulose	paper)	in	buffer	(.25M‐3	Tris	Base,	.19M‐3	Glycine,	10%Methanol)	for	
1hr	at	100V,	carriage	was	place	on	a	stir	plate	and	contained	an	ice	pack.	Membrane	
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was	then	rinsed	twice	in	1xTBS	and	allowed	to	rock	at	room	temperature	for	15min.	
Membrane	was	 rinsed	 twice	 in	1xTBS	and	agitated	 in	blocking	 agent	 (5%	non‐fat	
dried	milk	 in	 TBS)	 for	 1hr	 at	 room	 temperature.	Membrane	was	 rinsed	 in	 1xTBS	
with	10%	Tween20	(TTBS)	then	agitated	in	TTBS	for	15min.	Following	a	final	rinse,	
membrane	was	 placed	 in	 primary	 antibody	 solution	 (5%	milk	 in	 TTBS	with	 anti‐
NR2B	1:1000	(Millipore),	‐GR	1:5000	(Santa	Cruz),	or	‐pNR2B	(Cell	Signaling))	and	
agitated	overnight	at	4°C.	On	day	2,	membranes	were	rinsed	and	agitated	in	TTBS	in	
5min	intervals	for	a	total	of	20min.	They	were	placed	in	light‐proof	boxes	and	then	
agitated	 in	 fluorescent	 secondary	 anti‐body	 solution	 (5%	 milk	 in	 TTBS	 with	
IRDye800	 (Rockland	 Immunochemicals,	 Gilbertsville,	 PA,	 USA)	 for	 1hr	 at	 room	
temperature.	Following	a	final	rinse	in	TTBS,	membranes	were	imaged	on	Odyssey	
Infrared	 Imaging	 System	 (LI‐COR	 Biosciences,	 Lincoln,	 NE,	 USA)	 and	 quantified	
using	Image	J	software	(NIH).		
	
Statistical	Analysis	
	 Data	were	subjected	to	analysis	of	variance	for	the	effects	of	drug	treatment	
(ORG‐34517	 or	 placebo	 control	 Nutella®)	 occurring	 within	 each	 fluid	 treatment	
(EtOH	or	water).	No	main	effect	or	interaction	was	found	regarding	treatment	with	
ORG‐34517	or	placebo	on	any	measure	assessed.	Therefore,	all	data	were	collapsed	
across	 the	 variable	 and	 analyzed	 for	 the	 effects	 of	 fluid	 treatment.	 When	
appropriate,	 treatment	 was	 used	 as	 the	 between	 subjects	 and	 time	 (week	 or	
timepoint)	 as	 the	 within	 subjects	 factors.	 Correlations	 were	 determined	 using	
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Pearsons’s	 r.	 When	 appropriate,	 post	 hoc	 testing	 utilized	 Bonferroni	 t‐test.	
Significance	was	determined	at	p	<	0.05.	
Results	
Body	Weight	and	Food	Consumption	
	 Body	 and	 food	 weights	 were	 taken	 weekly	 on	 Monday	 prior	 to	 the	
introduction	 of	 EtOH	 and	 continued	 through	 Monday	 of	 week	 10.	 	 Data	 were	
subjected	 to	 analysis	 of	 variance	 and,	 while	 no	 differences	 were	 found	 between	
EtOH	 exposed	 and	 water	 treated	 control	 animals,	 an	 interaction	 was	 observed	
(F(8,112)	 =	 2.093,	 p=	 0.042).	 Post	 hoc	 analysis	 determined	 that	 water	 treated	
controls	 consumed	more	 food	 during	week	 6,	 as	 compared	 to	 values	 observed	 in	
weeks	1	and	3.	A	reduction	in	food	consumption	was	found	in	EtOH	exposed	animals	
during	week	 3,	 as	 compared	 to	week	 1	 (fig	 3.2a)	 (Food	 Intake	 (g):	 EtOH	 =165.1,	
±3.46,	Ctrl	=179.1,	±5.99).		
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Fig	 3.2a.	 No	 effects	 of	 ORG‐34517	 or	 placebo	 were	 observed	 in	 either	 EtOH	 or	 control	
animals	regarding	 food	consumption.	Weekly	 food	consumption	did	not	differ	significantly	
between	water	control	(n=4)	and	EtOH	exposed	(n=12)	animals	at	any	week.	Within	EtOH	
exposed	animals,	consumption	varied	only	between	weeks	3	and	4.	In	water	treated	control	
animals,	week	6	consumption	levels	differed	from	those	observed	during	week	3	and	week	3	
levels	 were	 elevated	 from	 week	 1.	 	 Average	 food	 consumption	 (g)	 =	 172.0	 ±4.65	 (*=as	
compared	to	week	4;	**=as	compared	to	week	1;	***=as	compared	to	week	3,	p<0.005) 
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Weights	 did	 not	 differ	 significantly	 between	 treatment	 groups	 prior	 to	
experimentation.	No	significant	effects	of	treatment	were	found	during	any	of	the	9	
weeks.	A	main	effect	of	 time	was	observed	 (F(8,112)	=	502.8,	p<0.001),	 such	 that	
animals	gained	a	significant	amount	of	weight	during	each	week	of	the	experiment	
(fig	3.2b)	(Final	weights	(g):	EtOH=	451.9,	±10.2,	Ctrl	=	475.5,	±23.7).		
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Fig	3.2b.	No	effects	of	ORG‐34517	or	placebo	were	observed	in	either	EtOH	(n=12)	
or	 control	 animals	 (n=4).	 No	 treatment	 dependent	 changes	 in	 weight	 gain	 were	
found;	animals	gained	a	gradual	but	significant	amount	of	weight	over	the	course	of	
the	study.	Average	weight	gain	(g)=	239.2	±9.36.	 (*=	as	compared	to	week	1;	$=as	
compared	to	week	4;	**=as	compared	to	week	6;	p<0.005	for	all). 
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Ethanol	Consumption	and	Blood	Ethanol	Concentration	
	 Total	fluid	consumption	was	calculated	for	EtOH	exposed	animals	by	adding	
total	volume	of	EtOH	(ml/kg)	to	the	total	volume	of	water	(ml/kg)	consumed.	This	
value	was	compared	to	total	volume	of	water	(ml/kg)	consumed	by	control	animals.	
A	significant	interaction	was	found	between	treatment	and	drinking	week	(F(8,112)	
=	 31.2,	 p<0.01),	 although	 no	 difference	 in	 total	 fluid	 consumption	 was	 found	
between	 animals	 exposed	 to	 EtOH	 and	 those	 receiving	 only	 water	 at	 any	 week.		
However,	 post	 hoc	 testing	 reveal	 that	 water	 treated	 control	 animals	 consumed	
significantly	 less	 fluid	 in	 the	 final	4	weeks	 (weeks	6‐9)	as	 compared	 to	 the	 first	5	
weeks,	while	this	decline	occurred	later	in	EtOH	exposed	animals,	during	weeks	7‐9	
(fig	3.3).		
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Figure	 3.3.	 Total	 fluid	 consumed	 by	 water	 control	 (n=4)	 and	 EtOH	 exposed	 (n=12)	
animals.	 No	 significant	 effect	 of	 ORG‐34517	 or	 placebo	 was	 found,	 no	 significant	
differences	were	found	between	water	control	animals	and	EtOH	exposed	animals.	Fluid	
consumption	in	control	animals	decreased	during	week	6,	remaining	stable	thereafter;	in	
EtOH	 animals,	 this	 decrease	 was	 evident	 beginning	 in	 week	 7,	 suggesting	 a	 possible,	
though	not	significant,		influence	of	Nutella®	(*	=	as	compared	to	weeks	1‐5,	p<.05;	**=as	
compared	to	weeks	1‐6	water	controls,	p	<	.05).
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Analysis	of	the	consumption	pattern	within	EtOH	exposed	animals	revealed	a	
significant	 interaction	 between	 the	 type	 of	 fluid	 consumed	 (EtOH	 or	 Water)	 and	
time	 (week)	 (F(8,	 88)=	13.2,	 p<0.001).	 Animals	 consumed	more	water	 than	EtOH	
during	 all	 but	weeks	 3,	 5	 and	 7‐9	 (fig	 3.3a).	 EtOH	 consumption	 remained	 steady,	
with	 a	 decrease	 in	 consumption	 observed	 only	 during	week	 7	 (3.4a).	 Figure	 3.4b	
depicts	 the	 average	 dose	 of	 EtOH	 (g/kg)	 animals	 consumed	 each	 week	 (average	
weekly	 dose	 (g/kg):	 3.17,	 ±0.544).	 Distribution	 of	 the	 average	 BEC	 (mg/dl)	 is	
detailed	 in	 figure	 3.4c	 and	 depicts	 a	 wide	 array	 of	 BECs,	 ranging	 from	 4.2‐101.0,	
with	the	average	animal	obtaining	a	BEC	of	32.3	±9.5		(fig	3.4d).	
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Fig	 3.4a.	 No	 effects	 of	 ORG‐34517	 or	 placebo	 were	 observed	 in	 either	 EtOH	 or	 control	
animals	regarding	 food	consumption.	Weekly	 food	consumption	did	not	differ	significantly	
between	water	control	(n=4)	and	EtOH	exposed	(n=12)	animals	at	any	week.	Within	EtOH	
exposed	animals,	consumption	varied	only	between	weeks	3	and	4.	In	water	treated	control	
animals,	week	6	consumption	levels	differed	from	those	observed	during	week	3	and	week	3	
levels	 were	 elevated	 from	 week	 1.	 	 Average	 food	 consumption	 (g)	 =	 172.0	 ±4.65	 (*=as	
compared	to	week	4;	**=as	compared	to	week	1;	***=as	compared	to	week	3,	p<0.005)
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Fig	 3.4b.	 	 Average	 weekly	 dose	 of	 EtOH	 (g/kg)	 remained	 steady	 throughout	 the	
experiments	(n=12),	with	the	exception	of	a	decrease	in	consumption	occurring	during	
week	7.	Average	dose	(g/kg)	=	3.17	±0.54.	(*=as	compared	to	week	1,	p	<	0.05) 
*
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Fig	3.4c.	Distribution	of	the	average	EtOH	dose	(g/kg/exposure)	(n=12)	given	intermittent	
access	to	20%	EtOH	(n=12).	IA	model	produced	a	wide	array	of	EtOH	consumption,	ranging	
from	 0.6‐5.1	 g/kg/exposure,	 with	 the	 average	 animals	 self‐administering	 3.28,	 ±0.54	
g/kg/exposure. 
Fig	3.4d.	Distribution	of	 the	 average	BEC	 (mg/dl)	 (n=12)	 given	 intermittent	 access	 to	20%	
EtOH.	IA	model	produced	a	wide	array	of	BECs,	ranging	from	4.2‐101.0,	with	of	32.3	±9.5. 
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Corticosterone	Analysis	
	 Analysis	of	plasma	CORT	 levels	 revealed	no	effect	of	EtOH	treatment,	but	a	
main	effect	of	day	(F(2,	28)=19.57,	p<0.001).	CORT	plasma	levels	assessed	at	T2	(6	
days	following	the	withdrawal	of	EtOH)	were	significantly	elevated	in	all	animals,	as	
compared	to	those	measured	at	either	baseline	or	following	1Hr	of	EtOH	exposure	
(fig	 3.5a).	 However,	 data	 did	 trend	 toward	 patterns	 of	 elevations	 previously	
demonstrated	by	these	investigators	(table	3.2).	Specifically,	CORT	elevations	were	
greater	 in	 EtOH	 exposed	 as	 compared	 to	water	 treated	 control	 animals	 following	
1hr	of	access	to	EtOH	as	well	as	during	protracted	EWD,	though	levels	did	not	reach	
significance.		
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Figure	3.5a.	Plasma	CORT	 levels	 recorded	at	baseline,	1hr	 following	exposure	 to	20%	
EtOH,	and	T2	(time	of	sacrifice).		No	effect	of	EtOH	treatment	was	found.	Plasma	CORT	
levels	 are	 significantly	 elevated	 in	 all	 animals	 at	 the	 final	 time	 point,	 no	 significant	
difference	was	found	among	EtOH	exposed	(n=12)	and	water	control	animals	(n=4).	(*=	
compared	to	T0	and	following	1Hr	of	EtOH	exposure,	p	<	0.05) 
Table	3.2 
Plasma	Corticosterone	Levels	(ng/ml) 
	  
	 	 	 																T0	 																							1Hr	EtOH	 	 	T2 
	 	 	 	 	 	 									Exposure				 													 
	 	 	 								M	 							SEM	 							M	 								SEM	 								M	 							SEM 
Water	Control	(n=4)									164.8					±47.8														130.0					±34.0															290.9				±60.9 
EtOH	Exposed	(n=12)						173.4					±23.3														215.0					±18.6															384.1				±40.5 
	 	 	 	 	  
	 	 	  
* 
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Correlational	 analysis	 regarding	EtOH	exposed	 animals	 revealed	 significant	
findings.	As	previously	demonstrated,	CORT	levels	assessed	prior	to	EtOH	exposure	
were	positively	correlated	(r=	0.651,	p=0.0219)	with	subsequent	EtOH	intake	(g/kg)	
(fig	 3.5b).	 However,	 contrary	 to	 previous	 findings,	 neither	 BEC	 (3.5c),	 nor	 CORT	
levels	obtained	during	protracted	EWD	(T2)	(3.5d)	correlated	with	those	assessed	
after	1Hr	of	EtOH	exposure.			
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Figure	3.5b.	Plasma	CORT	concentration	prior	to	and	following	1Hr	of	EtOH	exposure.	
Animals	 with	 higher	 levels	 of	 plasma	 CORT	 prior	 to	 EtOH	 exposure	 consumed	
significantly	higher	levels	of	20%	EtOH. 
r(9)=0.4010 
p=0.186 
Figure	 3.5c.	 Plasma	 CORT	 concentration	 following	 1Hr	 of	 exposure	 to	 EtOH	 is	 not	
associated	with	BEC	at	the	same	time	point.	 
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Figure	3.5d.	Plasma	CORT	levels	measured	at	baseline	do	not	significantly	correlate	with	
those	following	6days	of	EWD	(T2).	 
r(9)=0.501 
p=0.0973 
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Acoustic	Startle	Reflex	
	 FSR	(fig	3.6):	 Data	analysis	revealed	no	effects	of	treatment,	but	a	main	effect	
of	time	(F(2,28)=	4.5,	p	=	0.019).	Post	hoc	testing	revealed	that	all	animals	displayed	
an	elevated	FSR	at	T2,	when	EtOH	treated	animals	had	experienced	26hrs	of	EWD.	
Interestingly,	 and	 consistent	 with	 previous	 data,	 EtOH	 exposed	 animals	 (n=12)	
responded	 more	 robustly	 during	 this	 time	 point	 than	 did	 control	 animals	 (n=4),	
though	these	differences	did	not	reach	significance	(table	3.3).		
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Table	3.3 
Magnitude	of	Startle	Reflex	(arbitrary	units) 
	  
	 	 	 										 											
	 	 	 	 		T0	 	 															T1	 				 															T2 
	 	 	 								M	 							SEM	 							M	 								SEM	 								M	 							SEM 
Water	Control	(n=4)									57.3					±16.9															112.5					±23.5														72.8				±35.2 
EtOH	Exposed	(n=12)						45.4					±16.9															189.3					±40.6														66.1				±17.5 
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Figure	3.6.		Magnitude	of	the	startle	response	to	the	first	presentation	of	a	120dB	pulse	
as	measured	at	baseline(T0)	and	26hrs	(T1)and	5days	(T2)	following	EtOH	withdrawal.	
No	significant	differences	were	found	regarding	EtOH	treatment,	however,	all	animals	
demonstrated	elevations	in	response	during	acute	EWD..	(*=		compared	to	T0,	p	<	0.05) 
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Habituation:	 Analysis	 of	 habituation	 data	 revealed	 no	 significant	 effects	
regarding	either	treatment	or	day.		
PPI	(fig	3.7):	 Data	were	 initially	 analyzed	within	 each	 level	 of	 prepulse	 for	
the	 effects	 of	 treatment	 and	 time.	 As	 no	 main	 effect	 or	 interaction	 was	 found	
regarding	treatment,	data	were	collapsed	across	the	variable	and	analyzed	in	a	two‐
way	 repeated	measure	 ANOVA	 (level	 x	 time	 (day)).	 A	 significant	 interaction	 was	
detected	(F(4,60)	=	4.383,	p	=	0.004.	Post	hoc	testing	revealed	that	both	the	79	and	
87dB	level	prepulse	was	sufficient	to	significantly	reduce	inhibition,	as	compared	to	
baseline	values	(fig	3.7).	Reductions	of	38	and	46%	were	observed,	respectively.		
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Fig	3.7.	Percent	of	prepulse	inhibition	(PPI)	 is	the	ability	of	animals	(n=16)	to	inhibit	the	
startle	response	to	a	pulse	(12dB)	when	the	pulse	 is	preceded	by	a	non‐startling	 level	of	
prepulse.	The	79	and	87dB	prepulse	levels	were	able	to	inhibit	startle	response	at	T2,	as	
compared	to	baseline	(*	=	as	compared	to	T0,	p<	0.05).	 
* 
*
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Protein	Analysis	
A	one‐way	ANOVA	was	used	to	analyze	treatment	effects	in	protein	receptor	
expression	of	NR2B	subunits	and	GR.	Initial	immunoblotting	experiments	using	the	
pNR2B	 antibody	 failed	 to	 produce	 measurable	 results.	 Communication	 with	 Cell	
Signaling	 determined	 that	 the	 antibody	 was	 ineffective	 at	 targeting	 the	 protein.	
Replacement	antibody	was	subsequently	delivered	and	verified	to	be	functional	and	
re‐analysis	 of	 tissue	 revealed	detectable	 levels	 of	 protein.	However,	 due	 to	 a	high	
background	signal	data	were	not	able	to	be	analyzed.	Subsequent	experiments	will	
work	 toward	 optimizing	 antibody	 concentrations.	 No	 effect	 was	 found	 regarding	
EtOH	induced	changes	in	NR2B	or	GR.		
	
Discussion	
	
	 The	most	surprising	finding	in	the	present	study	was	that	ORG‐34517	had	no	
significant	effect	upon	EtOH	consumption	or	EWD.	The	structure	of	ORG‐34517	 is	
similar	 to	 that	of	RU‐486	and	was	therefore	expected	to	have	the	same	properties	
with	 regards	 to	 EtOH	 consumption.	 Further,	 the	 efficacy	 of	 ORG‐34517	 was	
comparable	to	that	of	an	equal	dose	of	RU‐486	at	blocking	learning	and	memory,	as	
administration	 of	 either	 drug	 was	 as	 effective	 at	 reducing	 immobility	 in	 an	
inescapable	 forced	 swim	 test	 (Bilang‐Bleuel	 et	 al,	 2005).	 As	 previously	 explained,	
the	 drugs	 differ	 largely	 based	 upon	 their	 pharmacological	 actions	 at	 the	 PR,	with	
RU‐486	 but	 not	 ORG‐34517,	 acting	 to	 antagonize	 this	 receptor.	 In	 this	 study	
100mg/kg	 of	 either	 drug	 was	 administered	 subcutaneously	 (s.c.),	 15min	 prior	 to	
testing	 procedures.	 As	 route	 of	 administration	 can	 have	 a	 large	 impact	 on	 the	
bioavailability	of	a	drug,	it	is	possible	that	both	the	dose	and	timing	of	drug	delivery	
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could	 be	 adjusted	 to	 accommodate	 the	 protocol	 used	 in	 these	 studies.	 First,	 the	
dosage	 may	 need	 to	 be	 elevated,	 as	 p.o.	 administration	 allows	 for	 first‐pass	
metabolism,	 likely	 reducing	 the	 drug‐plasma	 concentrations	 (doses	 as	 high	 as	
50mg/kg	i.p.	have	been	reported	(Jaquot	et	al.,	2008).	Additionally,	as	compared	to	
s.c.	administration,	p.o.	delivery	results	in	slower	absorption,	therefore	30mins	may	
be	 insufficient	 time	 for	 the	 drug	 to	 reach	 maximal	 concentrations	 in	 the	 blood	
stream.	 Subsequent	 studies	 should	 include	 an	 analysis	 of	 the	 pattern	 of	
consumption	 elicited	 by	 the	 animals,	 as	 it	 is	 possible	 that	 administration	 of	 ORG‐
34517	may	shift	 this	pattern.	While	 these	studies	 suggest	 there	are	advantages	 to	
using	an	outbred	rodent	to	study	EtOH	consumption,	a	selectively	bred	line	may	be	
better	suited	for	ORG‐34517dosing	studies.	Using	such	a	line	would	greatly	reduce	
EtOH	exposure	times	prior	to	administration	of	ORG‐34517,	as	these	animals	tend	
to	 acquire	 and	 stabilize	 elevated	 levels	 of	 consumption	quickly.	Because	 the	P	 rat	
shows	 similar	 CORT	 and	 EtOH	 preference	 as	 individuals	 who	 have	 a	 genetic	
predisposition	 to	 developing	 AUDs,	 they	 present	 as	 a	 likely	 candidate	 for	 such	
studies.		
	 	 The	 present	 study	 replicated	 much	 of	 the	 data	 discussed	 in	 the	
previous	chapter;	data	from	both	experiments	are	presented	in	tables	3.4‐3.7.	
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Table	3.4 
Average	Food	Consumption	and	Weight	Gain	(all	animals) 
	 		 	 										 	  
	 	 	 	 Food	(g)																			Weight	(g)	 				 			 
	 	 	 								M	 							SEM	 							M	 								SEM	 	 
Study	1	 (n=32)							160.9					±2.97															231.1					±11.95 
Study	2	 (n=16)							172.0					±4.65															239.2					± 9.36	 	  
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Table	3.5 
Average	Fluid/Ethanol	Consumption	and	BEC	(EtOH	animals	only)		  
	 	 	 		 	 										 	  
	 	 	 							Water	(ml/kg)	 						EtOH	(ml/kg)	 			EtOH	(g/kg)										BEC	(mg/dl)	 		
	 	 	 								M	 							SEM	 							M	 								SEM	 			M								SEM												M								SEM	 
Study	1	 (n=24)								44.3					±1.90															25.2					±2.94	 		3.79				±2.94	 						42.0					±7.10		  
Study	2	 (n=12)								48.7					±1.04															24.9					±3.59	 		3.28				±0.54	 						32.3					±9.50	 
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Table	3.6 
Corticosterone	(ng/ml)		 	 	 		 	 										 	  
	 	 	 							 
	 	 	 																											T0	 							 															T1		 																								T2				 			 
	 	 	 																					M	 							SEM	 							M	 								SEM	 			M								SEM	 
Study	1	 	 									 
	 Water	Control	(n=		8)*							204.8					±20.8															182.0					±20.5	 		291.4		±38.9			
	 EtOH	Treated		(n=23)*						171.9					±12.4															174.6					±12.0	 		369.5		±19.1	 
Study	2	 	 							 
	 Water	Control			(n=		4)								164.9					±47.8															130.0					±34.0	 		290.9		±60.9			
	 EtOH	Treated				(n=12)							173.4					±23.3																215.0					±18.6	 		384.1		±40.5		
 
(*At	T2:	Water	control	n=3;	EtOH	treated	n=12) 
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Table	3.7 
First	Startle	Reflex	(arbitrary	units) 
	 	 	 		 	 										 	  
	 	 	 								 															T0	 							 															T1		 																												T2							 			 
	 	 	 									 										M								SEM	 									M									SEM	 								M							SEM	 
Study	1	 	 									 
	 Water	Control	(n=10)								44.7					±3.67																58.1					±		9.93	 						110.3		±14.02				  
														EtOH	Treated		(n=21)								42.4					±5.67															158.5				±35.34	 						141.4		±26.94	 
Study	2	 	 							 
	 Water	Control			(n=		4)							57.3					±16.9															112.5					±23.5	 								72.8		±35.2						  
														EtOH	Treated				(n=12)						45.4					±16.9																189.3					±40.6	 								66.1		±17.5	 
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General	Discussion	
	
This	dissertation	used	 a	 voluntary	model	 of	EtOH	 consumption	 to	 examine	
the	 relationship	between	CORT	 levels	and	EtOH	consumption.	 	 Study	1	 revealed	a	
positive	 correlation	 between	 baseline	 CORT	 and	 subsequent	 levels	 of	 EtOH	
consumption.	The	 study	 also	 characterized	 the	pattern	of	 consumption	 associated	
with	IA	access	to	20%	EtOH	in	the	Long‐Evans	rat	and	suggests	that	this	pattern	is	
sufficient	to	produce	physical	dependence	as	evidenced	by	alterations	in	ASR	during	
EWD.	 Finally,	 ASR	 data	 suggest	 the	 animals	 used	 in	 these	 studies	 may	 not	 have	
reached	full	maturity	prior	to	the	first	EtOH	exposure.	Study	2	tested	the	hypothesis	
that	 blocking	 the	 GR	 with	 the	 selective	 antagonist	 ORG‐34517	 would	 result	 in	 a	
reduction	 in	 both	 EtOH	 consumption	 and	 subsequent	 EWD	 as	measured	 by	 ASR.	
Contrary	to	the	hypothesis,	ORG‐34517	produced	no	effects	on	EtOH	consumption	
or	EWD.		
	
Corticosterone	
The	interaction	between	CORT	and	EtOH	consumption	has	been	well	studied.	
As	a	positive	reinforcer,	 the	presentation	or	elevation	of	CORT	can	have	a	positive	
influence	on	behavior.	Therefore,	it	is	not	surprising	that	exogenous	administration	
of	 CORT	 or	 stimulating	 the	 HPA‐axis	 through	 the	 presentation	 of	 a	 stressor	 can	
elevate	EtOH	consumption	(Becker	et	al,	2013;	Falke	et	al,	1994a,b;	Falke	&	Hansen,	
1995;	 Hansen	 et	 al,	 1995).	 	 However,	 fewer	 studies	 have	 investigated	 how	 basal	
levels	of	CORT	could	influence	consumption.	The	finding	that	basal	CORT	levels	are	
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predictive	 of	 subsequent	 EtOH	 consumption	 in	 the	 outbred	 Long‐Evans	 rat	 is	
consistent	 with	 pre‐clinical	 investigations	 using	 selectively	 bred	 rat	 lines.	 For	
example,	elevations	in	both	basal	CORT	levels	and	EtOH	consumption	are	evident	in	
the	EtOH	preferring	P	rat	as	compared	to	the	non‐EtOH	preferring	NP	rat	(Prasad	&	
Prasad,	1995).	While	the	data	presented	here	are	correlational	and	do	not	allow	us	
to	 infer	 causation,	 a	 possible	 reason	 that	 animals	 with	 elevated	 levels	 of	 CORT	
demonstrate	 increased	 consumption	may	 be	 due	 to	 variations	 in	 the	 GR	 protein.	
Recent	 investigations	have	 indicated	 that	polymorphisms	 in	 the	GR	are	associated	
with	 elevated	 cortisol	 secretion	 following	 the	 presentation	 of	 psychosocial	 stress	
(i.e.,	public	speaking)	(Wust	et	al,	2004).	Genetic	variations	in	GR	are	also	associated	
with	 elevations	 in	 basal	 cortisol	 levels	 at	 bedtime	 (Rosmond	 et	 al,	 2000).	
Additionally,	Disrivieres	and	colleagues	 (2011)	 investigated	 the	 role	of	 the	NR3C1	
GR	 gene	 in	 a	 large	 population	 of	 14	 year	 olds	 (n=4534).	 This	 group	 found	 that	
variation	in	this	gene	was	associated	with	initiation	of	drinking,	as	female	subjects	
with	the	minor	allele	reported	using	alcohol	repeatedly	as	compare	to	non‐alcohol	
using	subjects.	Together	these	data	suggest	a	role	for	the	GR	in	mediating	HPA‐axis	
activity	and	sensitivity,	and	 that	 this	may	 influence	alcohol	use.	While	Subsequent	
investigations	 are	 necessary	 to	 further	 understand	 the	 correlation	 between	 CORT	
and	EtOH	consumption,	the	current	findings	may	be	helpful	in	the	clinical	setting,	as	
elevated	levels	of	baseline	CORT	could	aid	in	identifying	individuals	who	may	be	at	
risk	for	developing	AUD.	
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Intermittent	Access	Model	of	EtOH	Exposure	as	a	Model	for	Dependence	
To	fully	investigate	the	complex	problem	of	alcohol	abuse,	it	is	necessary	to	
have	 numerous	 methods	 by	 which	 use	 and	 dependence	 can	 be	 explored.	 Such	
models	 should	 include	 the	 use	 of	 genetically	 manipulated	 and	 selectively	 bred	
animals,	 models	 of	 forced	 EtOH	 administration,	 and	 models	 of	 voluntary	
consumption,	 in	 which	 individual	 variations	 can	 be	 expressed.	 In	 utilizing	 a	
voluntary	model	of	EtOH	consumption,	individual	differences	in	CORT	levels,	which	
were	 predictive	 of	 EtOH	 intake,	 were	 detected.	 This	 finding	 would	 have	 been	
masked	in	a	model	of	forced	EtOH	exposure.	As	individual	differences	are	known	to	
influence	 alcohol	 consumption	 and	 dependence	 in	 the	 human	 population,	 having	
preclinical	models	in	which	they	can	be	explored	is	important	to	better	understand	
AUD.		
Data	 presented	 here	 suggest	 the	 IA	 model	 could	 be	 used	 to	 explore	 the	
development	 of	 dependence	 in	 the	 outbred	 laboratory	 rat,	 despite	 levels	 of	
consumption	 that	 may	 be	 characterized	 as	 modest.	 Specifically,	 in	 study	 1	 EtOH	
exposed	 animals	 demonstrated	 elevated	 FSR	 during	 both	 acute	 and	 protracted	
EWD,	 as	 compared	 to	 animals	 receiving	 only	 water.	 While	 not	 significant,	 data	
collected	in	study	2	were	similar	in	that	FSR	was	elevated	in	EtOH	exposed	animals	
during	 the	 acute	 phase	 of	 EWD.	 Following	 IA	 to	 20%	EtOH	 alterations	 in	 NMDA‐
induced	 currents	 and	 changes	 in	 phosphorylation	 of	 the	NR2B	 subunit	 have	been	
found	in	regions	of	the	striatum	(Wang	et	al,	2010).	This	is	important	as	alterations	
in	 these	 receptor	 proteins	 have	 been	 implicated	 in	 mediating	 signs	 of	 EWD,	
including	anxiety.	In	fact,	short‐term	exposure	to	moderate	concentrations	of	EtOH	
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has	been	 shown	 to	produce	measurable	 changes	 in	anxiety‐related	EWD	behavior	
(Bonassoli	 et	 al,	 2011;	 Cabral	 et	 al,	 2006;	 Kayir	 et	 al,	 2010).	 Data	 reported	 here	
support	these	findings	and	suggest	that	IA	to	EtOH	may	produce	measurable	signs	of	
EWD,	 which	 is	 indicative	 of	 physical	 dependence.	 However,	 a	 recent	 study	
employing	 the	 IA	 model	 found	 no	 elevations	 in	 anxiety,	 as	 measured	 by	
performance	 on	 the	 elevated	 plus	 maze	 (EPM).	 In	 this	 study	 by	 Cippitelli	 et	 al	
(2012)	EPM	performance	was	assessed	following	21	exposures	to	EtOH	(equivalent	
to	that	in	study	1)	and	30hr	following	the	removal	of	EtOH	(FSR	assessment	began	
at	26hr	in	study	1).	In	comparing	the	Cippitelli	research	and	the	current	study,	two	
procedural	differences	were	noted.	The	 current	 studies	used	Long‐Evans	 rats	 that	
were	 PND60,	 while	 the	 Cippitelli	 study	 used	 Wistar	 rats	 at	 PND75‐79.	 A	 direct	
comparison	of	 consumption	 levels	between	 the	Cippitelli	 and	 current	 study	 is	not	
possible,	 as	 the	 former	does	not	mention	 controlling	 for	 leakage	when	 calculating	
the	amount	of	EtOH	consumed.	However,	both	studies	assessed	BEC	following	1hr	of	
EtOH	exposure.	A	comparison	of	these	values	show	BEC	levels	in	study	1	are	almost	
twice	 those	 seen	 the	 Cippitelli	 study.	 In	 fact,	 IA	 exposure	 in	 the	 Cippitelli	 study	
resulted	in	one	animal	having	BEC	higher	than	40mg/dl	(n=8;	~12%),	whereas	8	of	
24	animals	obtained	this	level	in	study	2	(~33%).	From	this	comparison	it	cannot	be	
concluded	 that	 that	 the	 animals	 in	 the	 Cippitelli	 study	 never	 reached	 higher	 BEC	
levels	 during	 EtOH	 exposure,	 but	 it	 does	 provided	 evidence	 that	 the	 pattern	 of	
drinking	differs	between	the	two	studies.	This	 is	surprising,	as	Simms	et	al	(2008)	
compared	consumption	and	BEC	between	 the	 two	strains	using	 IA	access	 to	EtOH	
and	 reported	 no	 significant	 differences	 in	 either	 measure.	 Further,	 Simms	 and	
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colleagues	found	that,	following	30min	of	EtOH	access,	25%	of	the	Long‐Evans	and	
70%	 of	 the	 Wistar	 rats	 had	 BEC	 above	 40mg/dl.	 In	 the	 current	 study,	 there	 is	
evidence	 that	 animals	 drink	 rapidly	 during	 initial	 exposure	 to	 EtOH	 and	
subsequently	 obtain	 elevated	BEC	 levels.	 Evidence	of	 this	 occurrence	 is	 lacking	 in	
the	Cippitelli	study	and	may	account	of	the	lack	of	EWD	anxiety.			
ASR	data	suggest	 that	 the	animals	used	 in	 these	studies	may	not	have	 fully	
matured	 prior	 to	 the	 introduction	 of	 EtOH.	 Specifically,	 ASR	 data	 collected	 at	
baseline	 revealed	 very	 little	 habituation	 or	 inhibition	 in	 the	 presence	 of	 the	
prepulse,	a	state	that	is	indicative	of	adolescence	(Brunell	&	Spear,	2006).	Research	
suggests	 that	 adolescents	 experience	 fewer	 effects	 that	 are	 associated	 with	 the	
negative	 regulation	 of	 EtOH	 such	 as	 sedation	 and	 withdrawal,	 but	 are	 especially	
sensitive	to	the	neurodegenerative	effects	that	are	associated	with	the	development	
of	dependence.	Preclinical	data	support	this,	as	adolescent	rats	consume	more	EtOH	
than	 adult	 animals	 (Brunell	 and	 Spear,	 2005;	 Doremus	 et	 al.,	 2005)	 and	 animals	
display	greater	EWD	when	exposure	begins	in	adolescence	as	compare	to	adulthood	
(Wills	et	al,	2009).	Regarding	the	previously	discussed	Cippitelli	study,	it	is	possible	
that	 age	 is	 the	 underlying	 reasons	 these	 animals	 display	 a	 different	 pattern	 of	
consumption	as	compared	to	both	the	present	study	and	that	conducted	by	Simms	
and	colleagues.	Specifically,	in	the	latter	2	studies,	animals	were	PND60	when	EtOH	
exposure	began	as	compared	to	the	Cippitelli	study,	in	which	animals	were	PND75‐
79.		As	more	labs	are	using	the	IA	model,	it	will	be	important	to	determine	if	age	is	a	
crucial	factor	regarding	EtOH	consumption	and	the	development	of	dependence.		
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Glucocorticoid	Receptor	Antagonists	
It	has	long	been	accepted	that	the	environment,	genes,	and	their	interactions	
play	 defining	 roles	 in	 the	 addiction	 process.	 Indicative	 of	 the	 complex	 behavioral	
profile	 for	 alcoholism,	 it	 is	 likely	 that	 an	 array	 of	 gene	 combinations	 are	 able	 to	
confer	 susceptibility	 for	 the	 disorder,	 including	 those	 involved	 in	 the	 synthesis,	
secretion,	and	expression	of	glucocorticoids	and	their	receptor	proteins.	Stress	can	
contribute	to	the	escalation	of	alcoholism	and	also	promote	relapse.	Preclinical	data	
support	 the	 importance	 of	 CORT	 in	 mediating	 EtOH	 consumption	 and	 its	
consequences.		For	example,	Koenig	and	Olive	(2004)	induced	EtOH	consumption	in	
the	 outbred	 Long‐Evans	 rat	 using	 sucrose	 fading	 and	 water	 deprivation.	 The	
researchers	 then	 allowed	 the	 animals	 one	 hour	 of	 access	 to	 both	water	 and	 10%	
EtOH.	 Administration	 of	 RU‐486	 (40mg/kg,	 i.p.)	 delivered	 immediately	 prior	 to	
introduction	of	EtOH	reduced	consumption	by	40%,	while	water	consumption	was	
unaffected.	 Recently,	 Vendruscolo	 and	 colleagues	 (2012)	 showed	 that	
administration	of	RU‐486	(sub‐cutaneous	pellet)	during	exposure	to	EtOH	via	vapor	
chamber	 (21days)	 prevented	 escalated	 responding	 on	 a	 progressive	 ratio	 task	
during	acute	EWD	(24hr).	Similar	results	were	reported	by	Simms	et	al	(2011),	as	
administration	 of	 RU‐486	 (30mg/kg,	 i.p.)	 attenuated	 reinstatement	 of	 EtOH	
responding	 following	 the	 delivery	 of	 the	 pharmacological	 stressor	 yohimbine	
(2mg/kg,	 i.p.)	 in	 the	Long‐Evans	 rat.	Research	 regarding	 the	efficacy	of	RU‐486	 in	
treating	EWD	includes	studies	using	both	short‐	and	long‐term	EtOH	exposure.	In	a	
short‐term	 model	 of	 binge‐like	 EtOH	 exposure,	 where	 EtOH	 is	 delivered	 intra‐
gastrically	 (i.g.)	 three	 times	 daily	 for	 4	 days,	 RU‐486	 (40mg/kg,	 s.c.)	 significantly	
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decreases	 the	 severity	 of	 behavioral	 abnormalities	 (e.g.	 tremor	 and	 “wet	 dog	
shakes”)	 10‐12hr	 following	 the	 final	 dose	 of	 EtOH	 (Sharrett‐Field	 et	 al,	 2013).	
Following	8	months	of	exposure	to	24%	v/v	EtOH	as	the	sole	source	of	fluid,	Jacquot	
and	colleagues	 (2008)	 found	 that	a	 single	dose	of	RU‐486	 (50mg/kg,	 i.p.)	 reduced	
handling‐induced	hyperexcitability	in	the	C57/BL10	strain	mice.	Further,	following	
assessment	of	withdrawal	symptoms,	animals	received	initial	exposure	to	an	object	
recognition	task.	Upon	retest,	 those	animals	not	 receiving	RU‐486	spent	and	equal	
amount	 of	 time	 exploring	 the	 novel	 and	 familiar	 objects,	 which	 is	 indicative	 of	
memory	deficits.	This	effect	was	attenuated	in	animals	treated	with	RU‐486.	As	RU‐
486	and	ORG‐34517	have	 similar	 chemical	 structures	 and	both	are	 antagonists	of	
the	GR,	 it	was	hypothesized	 that	administration	of	ORG‐34517	would	both	reduce	
EtOH	 consumption	 and	 attenuate	 signs	 of	 EWD.	 However,	 analysis	 of	 the	 data	
revealed	 that	 drug	 administration	 had	 no	 effect	 on	 consumption	 or	 EWD.	 This	
failure	 likely	 arose	 due	 to	 improper	 scheduling	 and	 drug	 dosage.	 However,	 the	
differences	regarding	activity	at	the	PR	cannot	be	overlooked.	Specifically,	RU‐486	is	
a	GR/PR	antagonist	whereas	ORG‐34517	is	a	selective	GR	antagonist,	with	minimal	
PR	binding	even	at	high	doses.	Therefore,	the	possibility	that	the	effects	of	RU‐486	
are	 PR	 mediated	 should	 be	 considered.	 In	 fact,	 several	 studies	 have	 shown	 that	
administration	 the	progesterone	metabolite	 allopregnanalone	 (ALLO),	which	 is	 an	
agonist	 of	 the	GABA‐A	 receptor,	 can	produce	 tolerance	 to	 the	 anxiolytic	 effects	 of	
EtOH	(Sharma	et	al,	2007),	 increase	responding	for	EtOH	(Janak	et	al,	1998;	Nie	&	
Janak,	2003),	 and	reduce	EWD‐induced	anxiety	 (Sharma	et	al.,	2007).	 It	 is	unclear	
how	blocking	the	PR	with	administration	of	RU‐486	affects	levels	of	progesterone	in	
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the	brain.	However,	it	is	conceivable	that	RU‐486	could	decrease	EtOH	consumption	
by	decreasing	 levels	of	progesterone	and	subsequently,	 levels	of	ALLO.	Evaluating	
levels	of	these	neurosteroids	in	the	brain	following	administration	of	RU‐486	would	
be	 helpful	 in	 determining	 their	 possible	 role	 in	 the	 attenuation	 of	 EtOH	
consumption.		
In	sum,	 these	 findings	add	 to	 the	growing	body	of	 literature	 that	advocates	
for	the	use	of	voluntary	intermittent	access	to	EtOH.	This	model	is	advantageous	in	
that	 it	 reflects	 real	 world	 factors	 such	 as	 voluntary	 consumption	 in	 a	 genetically	
heterogeneous	 population,	 and	 allows	 for	 individual	 differences	 in	 EtOH	 usage	 to	
manifest.	This	was	demonstrated	in	the	current	studies,	as	individual	basal	levels	of	
CORT	were	 found	to	be	correlated	with	subsequent	 levels	of	EtOH	consumption,	a	
fact	that	would	have	gone	unobserved	in	a	model	of	forced	exposure.	Characteristics	
regarding	the	pattern	of	EtOH	consumption	produced	by	IA	are	demonstrated	here	
and	it	is	suggested	that	this	pattern	is	capable	of	producing	physical	dependence,	as	
measured	by	ASR.	However,	ASR	data	 suggest	 that	 the	age	of	 the	animals	used	 in	
these	 and	 several	 other	 studies	 may	 influence	 findings	 regarding	 consumption	
patterns,	which	may	subsequently	influence	the	manifestation	of	EWD.	Finally,	these	
studies	 revealed	 that	 baseline	 CORT	 levels	 are	 predictive	 of	 subsequent	 EtOH	
consumption,	providing	further	evidence	that	the	hormone	and	its	receptors	may	be	
a	pharmacological	target	for	the	treatment	of	alcohol	abuse	disorders.		
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